



FORM PTO-1390 (REV. 1-98)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER GET-084	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371				U.S. APPLICATION NO. (If known, see 37 CFR 1.55) 09/72004	
INTERNATIONAL APPLICATION NO. PCT/TB99/01170		INTERNATIONAL FILING DATE June 23, 1999		PRIORITY DATE CLAIMED June 30, 1998	
TITLE OF INVENTION NOVEL ACYL-DIPEPTIDE-LIKE COMPOUNDS, A METHOD FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH PRODUCTS					
APPLICANT(S) FOR DO/EO/US BAUER et al					
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:					
<p>1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.</p> <p>2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.</p> <p>3. <input checked="" type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).</p> <p>4. <input type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.</p> <p>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))</p> <p>a. <input checked="" type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau).</p> <p>b. <input type="checkbox"/> has been transmitted by the International Bureau.</p> <p>c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</p> <p>6. <input checked="" type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)).</p> <p>7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))</p> <p>a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau).</p> <p>b. <input type="checkbox"/> have been transmitted by the International Bureau.</p> <p>c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</p> <p>d. <input type="checkbox"/> have not been made and will not be made.</p> <p>8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</p> <p>9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</p> <p>10. <input type="checkbox"/> A translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</p>					
Items 11. to 16. below concern document(s) or information included:					
<p>11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</p> <p>12. <input checked="" type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</p> <p>13. <input checked="" type="checkbox"/> A FIRST preliminary amendment.</p> <p><input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.</p> <p>14. <input type="checkbox"/> A substitute specification.</p> <p>15. <input type="checkbox"/> A change of power of attorney and/or address letter.</p> <p>16. <input checked="" type="checkbox"/> Other items or information: International Preliminary Examination Report Drawings (32 pages)</p>					

U.S. APPLICATION NO. (if known) 09/720045		INTERNATIONAL APPLICATION NO. PCT/TB99/01170		ATTORNEY'S DOCKET NUMBER GET-084	
17. <input checked="" type="checkbox"/> The following fees are submitted: BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$1070.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$930.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$790.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$720.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) \$98.00 ENTER APPROPRIATE BASIC FEE AMOUNT =				CALCULATIONS PTO USE ONLY \$1000.00	
				\$ 1000.00	
				\$	
				\$	
				\$	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$	
Total claims	- 20 =		x \$22.00	\$	
Independent claims	- 3 =		x \$82.00	\$	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)				+ \$270.00	\$
TOTAL OF ABOVE CALCULATIONS =				\$ 1000.00	
Reduction of 1/2 for filing by small entity, if applicable. A Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).				+	\$
SUBTOTAL =				\$ 1000.00	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$	
TOTAL NATIONAL FEE =				\$ 1000.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property				+	\$ 40.00
TOTAL FEES ENCLOSED =				\$ 1040.00	
				Amount to be refunded:	\$
				charged:	\$
PTO FORM 2038 is enclosed. a. <input checked="" type="checkbox"/> A check in the amount of \$ _____ to cover the above fees is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>02-2275</u> A duplicate copy of this sheet is enclosed.					
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.					
SEND ALL CORRESPONDENCE TO: Bierman, Muserlian and Lucas 600 Third Avenue New York NY 10016					
			 20311 PATENT TRADEMARK OFFICE		
			 SIGNATURE Charles A. Muserlian NAME 19,683 REGISTRATION NUMBER		

09720045

09/720045

526 Rec'd PCT/PTO 18 DEC 2000

3/A
22701
DT

Our Ref.: GEI-084

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: :
BAUER et al :
PCT/IB99/01170 : PCT Date: June 23, 1999
Serial No.: :
Filed: Concurrently Herewith :
For: NOVEL...SUCH PRODUCTS :
600 Third Avenue
New York, NY 10016

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Please amend this application as follows.

IN THE SPECIFICATION:

Page 1, before line 1, insert

--This application is a 371 of PCT/IB99/01170 filed June
23, 1999.--

IN THE CLAIMS:

Claim 3, line 2, cancel "or 2 viz." and insert --wherein--.

Claims 4 to 8, line 1 of each, cancel "anyone of claims 1 to
3 viz." and insert --claim 1 wherein--.

✓
Claim 11, line 2, cancel "anyone of claims 1 or 2" and insert
--claim 1--.

✓
Claims 12, 14 and 15, line 1 of each, cancel "claims 10 or 11"
and insert --claim 10--.

✓
Claim 13, line 1, cancel "anyone of claims 10 to 12" and
insert --claim 10--.

Claim 19, lines 1 and 2, cancel "anyone of claims 16 to 18"
and insert --claim 16--.


ADD THE FOLLOWING NEW CLAIM:

2
--20. A method of modulating immune responses in warm-blooded
animals comprising administering to warm-blooded animals an immune
responsive amount of a compound of claim 1 to modulate the same.--

REMARKS

The amendment is submitted to insert reference to the PCT
application and to remove multiple dependency from the claims.

Respectfully submitted,
BIERMAN, MUSERLIAN AND LUCAS


Charles A. Muserlian, #19,683
Attorney for Applicant(s)
Tel. # (212) 661-8000

CAM:sd
Enclosure: Return Receipt Postcard



09720045.121800

GEI-084

PreAmend
4B

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
JACQUES BAUER et al
Serial No.: 720,045
Filed: December 18, 2000
For: NOVEL...SUCH PRODUCTS

600 Third Avenue
New York N.Y. 10011
February 27, 2001

PRELIMINARY AMENDMENT

Asst. Commissioner for Patents
Washington, D.C. 20231


Sir:

Please amend this application as follows:

IN THE CLAIMS:

Cancel claims 1 to 3, 9 to 15 and add the following claims:

--20. A N-acyl-dipeptide of the formula



wherein R_1 and R_2 are each an acyl moiety of a saturated or unsaturated carboxylic acid of 2 to 24 carbon atoms unsubstituted or substituted with at least one member of the group consisting of -OH, alkyl and alkoxy of 1 to 24 carbon atoms, -NH₂, acyloxy of an organic carboxylic acid of 1 to 24 carbon atoms and acylamino and acylthio of a carboxylic acid of 1 to 24 carbon atoms and alkylthio of 1 to 24 carbon atoms, m, p and q are independently integers from

EL 78 304025 45
FEB 27 2001
Postage and Fees Paid
United States Postal
Service
Permit No. 1000
Washington, D.C. 20540
Postage and Fees Paid
United States Postal
Service
Permit No. 1000
Washington, D.C. 20540
Postage and Fees Paid
United States Postal
Service
Permit No. 1000
Washington, D.C. 20540

FEB 27 2001
D. Malone
Signature of person mailing paper or fee

RECEIVED

APR 02 2001


I TECH CENTER 1600/2900

1 to 10, n is an integer from 0 to 10, X and Y are independently hydrogen or an acid group selected from the group consisting of carboxyalkyl of 1 to 5 alkyl carbon atoms,

-CH-[(CH₂)_{m'}-COOH]-[(CH₂)_{n'}-COOH] where m' and n' are individually integers of 0 to 5, phosphonoalkyl of 1 to 5 carbon atoms, dihydroxyphosphonyloxyalkyl of 1 to 5 carbon atoms, dimethoxyphosphonyl, phosphone, hydroxy sulfonyl, hydroxysulfonyloxyalkyl of 1 to 5 carbon atoms in neutral or charged form with at least one of X and Y being other than hydrogen and A and B are individually selected from the group consisting of oxygen, sulfur and -NH-.

21. A compound of claim 20 wherein at least one of X and Y is other than hydrogen in salt form with a non-toxic, pharmaceutically acceptable base.

22. A compound of claim 20 having the formula



wherein R₁ and R₂ are individually an acyl moiety of a saturated or unsaturated carboxylic acid of 2 to 24 carbon atoms unsubstituted or substituted with at least one member of the group consisting of -OH, alkyl and alkoxy of 1 to 24 carbon atoms, -NH₂, acyloxy of an organic carboxylic acid of 2 to 24 carbon atoms and acylamino and acylthio of an organic carboxylic acid of 2 to 24 carbon atoms and alkylthio of 1 to 24 carbon atoms, m, p and q are individually

B1 integers from 1 to 10, n is an integer from 0 to 10 and X and Y are individually hydrogen or phosphono.--

Claim 4, cancel line 1 and insert ~~/A~~ compound of claim 20

B2 selected from the group consisting of 3-3- --


Claims 5 to 8, cancel line 1 of each and insert ~~/A~~ compound

B3 of claim 20 selected from the group consisting of 3- --


Add the Following Claims:

B4 --23. A compound of claim 20 having an (R) or (S) configuration and racemates thereof.

24. A process for the preparation of a compound of claim 20 which comprises blocking [(q + 1)] and ω amino groups of a compound of the formula $H_2N-(CH_2)_p-CH-NH_2-(CH_2)_{q+1}-COOH$ with a blocking agent, reacting the free carboxylic group with a reducing agent to form the corresponding alcohol, removing the amine blocking group in (q + 1) position to obtain the free amino group, reacting with a reactive derivative of an acid of the formula R_2OH to acylate the alcohol moiety, subjecting the product to hydrogenolysis to free the terminal amine to obtain the compound of the formula




which is reacted in the presence of a peptide condensing agent in an inert solvent with a ω -hydroxy, amino or thioamino acid of Formula III to obtain a compound of the formula




optionally protecting the alcohol groups with a substitution reagent in the presence of a coupling agent and optionally subjecting the product to a catalytic hydrogenation or deprotection step to obtain the compound of Formula I.


25. A process for the preparation of a compound of claim 22 comprising the (q + 1) and ω amine functions of a compound of the formula




with a blocking agent, reacting the latter with a reducing agent to reduce the free COOH to -CH₂OH, freeing the (q + 1) amine function, acylating the latter with a functional derivative of a carboxylic acid of the formula R₂-OH, subjecting the latter to hydrogenolysis to free the terminal amine to obtain a compound of the formula




reacting the latter with a compound of formula



in the presence of a peptide condensation agent in an inert solvent to obtain a compound of the formula



reacting the latter with a phosphorylating agent in the presence of a coupling agent, subjecting the resulting compound to a 2 step catalytic hydrogenation to free the -OH groups and the optionally present phosphate to obtain a compound of the formula



wherein Y is hydrogen or phosphono.

26. The process of claim 24 wherein the product is further reacted with a base to form the salt thereof.

27. The process of claim 25 wherein the product is further reacted with a base to form the salt thereof.

28. The method of claim 24 wherein $\text{R}_1\text{-OH}$ is 3-dodecanoyloxy-tetradecanoic acid.

29. The method of claim 24 wherein $\text{R}_2\text{-OH}$ is 3-hydroxytetradecanoic acid.

30. A method of inducing immuno-modulation in warm-blooded animals in need thereof comprising administering to said warm-blooded animals an immuno-modulating effective amount of a compound of claim 20.--

REMARKS

The amendment is submitted to conform the claims to the American practice.

Respectfully submitted,
Bierman, Muserlian and Lucas

By: Charles A. Muserlian
Charles A. Muserlian #19,683
Attorney for Applicants
Tel.# (212) 661-8000

CAM:ds
Encl.: Return receipt postcard

FIGURE 1

Induction of bone marrow stem cell proliferation




FIGURE 2

Induction of NO production in murine macrophage cells




FIGURE 3

Incubation of Dextran-FITC conjugate




FIGURE 4

Dextran-FITC conjugate take-up : Dose related effect at low concentrations




FIGURE 5

Dose related effect in terms of Dextran-FITC conjugate take-up at high concentrations




FIGURE 6

CD40 co-stimulating surface marker expression




FIGURE 7


Expression of CD86 co-stimulating surface marker

FIGURE 8


Expression of CD83 co-stimulating surface marker

FIGURE 9

Expression of CD80 co-stimulating surface marker





FIGURE 10


Effect of OM-294-MP and OM-294-DP products on α TNF production by predendritic cells at DC-6 stage



6/32


FIGURE 11

Effect of OM-294-MP and OM-294-DP products on IL-12 p70 production by predendritic cells at DC-6 stage (IFN = γ IFN)

**FIGURE 12**

Effect of OM-294-MP products on IL-12 p70 production by monocytes

(IFN = γ IFN)



7/32

FIGURE 13

ELISA 2 after the first immunization treatment





FIGURE 14

ELISA 3 after the second immunization treatment



8/32

FIGURE 15

ELISA 4 after the third immunization treatment





FIGURE 16

Antibody titer before and after one, two and three immunizations treatments



9/32

FIGURE 17

ELISPOT γ IFN-producing lymphocytes of inguinal lymph nodes stimulated by Pb CS
245 - 252 one week after the second immunization treatment





FIGURE 18


ELISPOT γ IFN-producing lymphocytes of the spleen stimulated by Pb CS 245 - 252
one week after the second immunization




10/32

FIGURE 19

ELISPOT γ IFN-producing lymphocytes of the spleen stimulated by Pb CS 245 - 252
one week after the second immunization

**FIGURE 20**


ELISPOT γ IFN-producing lymphocytes of the spleen stimulated by Pb CS 245 - 252
three weeks after the third immunization



11/32

FIGURE 21

Electrophoretogram of OM-294-DP alone, of Pb CS His6-242-310 antigen alone and of Pb CS His6-242-310 - OM-294-DP complex



12/32

FIGURE 22


IgG1 specific antibodies directed to H1N1

FIGURE 23


IgG2a specific antibodies directed to H1N1

FIGURE 24


IgM specific antibodies directed to H1N1

FIGURE 25


IgG1 specific antibodies directed to ovalbumin

FIGURE 26



IgG2a specific antibodies directed to ovalbumin

FIGURE 27

IgM specific antibodies directed to ovalbumin

14/32

FIGURE 28


IgG1 specific antibodies directed to TT

FIGURE 29


IgG2a specific antibodies directed to TT

FIGURE 30 (a)

Increase in the anti-gp63 immune response under the effect of OM-294-MP

adjuvant : Comparison with BCG




FIGURE 30 (b)




FIGURE 31 (a)

In vitro lymph node lymphocyte response derived from mice previously immunized in vivo with LmCPb antigen : effect of OM-294-MP adjuvant during the primary response




FIGURE 31 (b)




FIGURE 32 (a)

Increase in the anti-LmCPb immune response under the effect of OM-294-MP
adjuvant : Comparison with BCG




FIGURE 32 (b)






FIGURE 33



SYNTHESIS SCHEME 1

homoserine route



ASPARTIC ACID ROUTE

FIGURE 35

SYNTHESIS SCHEME 3

Bn = benzyl
Ph = phényl




FIGURE 36

SYNTHESIS SCHEME 4

Bn = benzyl

R = allyl

Y = protecting group





FIGURE 37

SYNTHESIS SCHEME 5

Bn = benzyl
R = allyl
Y = protecting group



23/32

FIGURE 38

SYNTHESIS SCHEME 6

Bn = benzyl
R = Allyl





FIGURE 39



Instrumentation: Micromass Quatro II (Z-spray), triple stage quadrupole

25/32

FIGURE 40




FIGURE 41

SPECTRUM 3

Diphosphorylated compound

ES-MS spectra (positive mode fragmentation)





FIGURE 42




monophosphorylated compound

SPECTRUM 5

¹H-NMR Spectrum


Solvent: (3:1 v/v) CDCl_3 : CD_3OD



Instrumentation: Varian Unity INOVA 500 MHz

monophosphorylated compound

SPECTRUM 6

¹³C-NMR SpectrumSolvent: CDCl_3 

Instrumentation: Bruker DPX 250 MHz

FIGURE 45




FIGURE 46





FIGURE 47

Spectrum 9 Diphosphorylated compound
 ^{31}P -NMR Spectrum

Solvent : CDCl_3



Instrumentation: Bruker DPX 300 MHz

NOVEL ACYL-DIPEPTIDE-LIKE COMPOUNDS, A METHOD FOR
PREPARING THE SAME AND PHARMACEUTICAL COMPOSITIONS
CONTAINING SUCH PRODUCTS


Insert
a

5 FIELD OF THE INVENTION

The present invention relates to the field of chemistry and more specifically to the field of medicinal chemistry

More particularly, it is directed to dipeptide-like compounds derived from hydroxylated amino acids, the free amine functional groups of which are subject to amide formation by means of fatty acids.

The invention is specifically concerned with N-acyl-dipeptide-like compounds at least one hydroxyl group of which is esterified by an acid group in the neutral or charged form, having the general formula I



15

(I)

wherein R₁ and R₂ each designate an acyl group derived from a saturated or unsaturated straight or branched chain-carboxylic acid having from 2 to 24 carbon atoms, which is unsubstituted or bears one or more substituents selected among hydroxyl, alkyl, alkoxy, acyloxy, amino, acylamino, acylthio and ((C₁₋₂₄)alkyl)thio groups,

20

subscripts m, p and q are integers ranging from 1 to 10,

subscript n is an integer ranging from 0 to 10,

X and Y each designate a hydrogen or an acid group either in neutral or charged form,

25

provided that at least one of substituents X and Y designates an acid group in neutral or charged form,

A and B designate, independantly from each other, an oxygen atom, a sulfur atom or an imino group -NH-.

30

Acid groups X and Y are preferably selected among the following groups :

- carboxy [(C₁₋₅)alkyl]

- CH-[(CH₂)_mCOOH] [(CH₂)_nCOOH] with m = 0 to 5 and n = 0 to 5

- phosphono [(C₁₋₅)alkyl]
- dihydroxyphosphoryloxy[(C₁₋₅)alkyl]
- dimethoxyphosphoryl
- phosphono
- 5 - hydroxysulfonyl
- hydroxysulfonyl[(C₁₋₅)alkyl]
- hydroxysulfonyloxy [(C₁₋₅)alkyl]

Where substituents X and/or Y designate an acid group in neutral form, reference is made to the free carboxylic, sulfonic or phosphoric form.

10 Where the acid group is in charged form, reference is made to the carboxylic, sulfonic or phosphoric salt form, namely by addition of an organic or mineral base, preferably one intended for therapeutic use. In case where bases are not intended for therapeutic use, such bases provide a means for easy identification, purification and separation.

15 Similar considerations apply where X and/or Y designate a carboxylalkyl, alcenylbiscarboxylic, hydroxysulfonyl, hydroxysulfonylalkyl, hydroxysulfonyloxyalkyl, phosphonoalkyl, phosphoryloxyakyl group.


 Salt forming bases intended for therapeutic use mainly include alkaline bases such as sodium, potassium or lithium hydroxides, 20 ammonium salts, alkali earth metal bases such as calcium or strontium hydroxide, magnesium salts, ferrous metal salts and the like, organic bases such as those derived from primary, secondary, tertiary amines such as methylamine, diethylamine, monoethanolamine, diethanolamine, benzylamine, N-methylbenzylamine, veratrylamine, trimethoxybenzylamine, 25 basic amino acids such as lysine and ornithine or amino sugars.

 Examples of bases not intended for therapeutic use are brucine, strychnine, agmatine, homarine, glucosamine, N-methylglucosamine or N-methylmorpholin. As previously stated, salts derived therefrom will serve as separation and identification means.

30 When m is equal to 1 and n is equal to 0, the molecule of interest derives from serine. Where m is equal to 2 and n is equal to 0, the molecule being considered derives from homoserine. If m is equal to 3 and n is equal to 0, reference is made to a pentahomoserine compound. If m is equal to 4 and n is equal to 0, reference is made to a hexahomoserine 35 compound.

Where p is equal to 3 and q is equal to 1, the product of interest may be a citrulline, ornithine or arginine compound. Where p is equal to 4 and q is equal to 1, reference is made to a homoarginine or lysine compound.

5 Among dipeptide-like compounds which are herein included, special attention is devoted to compounds of general formula I which are currently preferred :



10 (I')

wherein R_1 and R_2 each designate an acyl group derived from a saturated or unsaturated, straight or branched chain-carboxylic acid having from 2 to 24 carbon atoms, which is unsubstituted or bears one or more substituents selected from the group comprised of hydroxyl, alkyl, alkoxy, acyloxy, amino, acylamino, acylthio and ((C_{1-24})alkyl)thio groups,

15 subscripts m, p and q are integers ranging from 1 to 10,

subscript n is an integer ranging from 0 to 10,

X and Y each designate a hydrogen atom or a phosphono group.

and namely

20 3-(3-dodecanoyloxytetradecanoylamino) 9-(3-hydroxytetradecanoylamino)4-oxo-5-azadecan-1, 10-diol 1 and/or 10-dihydrogenphosphate and its addition salts formed with an organic or a mineral base,

25 3-(3-dodecanoyloxy-tetradecanoylamino) 9-(3-hydroxytetradecanoylamino)4-oxo-5-azadecan-1, 10-diol 1,10-bis(dihydrogenphosphate) and its addition salts formed with an organic or a mineral base,

30 3-(3-hydroxytetradecanoylamino) 9-(3-dodecanoyloxytetradecanoylamino)4-oxo-5-azadecan-1, 10-diol 1,10-bis(dihydrogenphosphate) and its addition salts formed with an organic or a mineral base,

3-(3-dodecanoyloxytetradecanoylamino) 9-(3-hydroxytetradecanoylamino) 4-oxo-5-azadecan-1, 10-diol 1-

dihydrogenophosphate and its addition salts with an organic or mineral base,

3-(3-hydroxytetradecanoylamino) 9-(3-dodecanoyloxytetradecanoylamino)4-oxo-5-azadecan-1, 10-diol 1-dihydrogenophosphate and its addition salts formed with an organic or a mineral base

3-(3-hydroxytetradecanoylamino) 9-(3-dodecanoyloxytetradecanoylamino)4-oxo-5-azadecane-1, 10-diol 10-dihydrogenophosphate and its addition salts formed with an organic or a mineral base.

R_1 and R_2 are meant to include saturated or unsaturated, branched or straight chain-acyl derivatives having a variable size chain, of distinct or identical nature, which can bear one or more substituents selected from the group comprised of alkyl, amino, acylamino, hydroxyl, alkoxy, acyloxy acylthio and alkylthio groups,

Examples of such acylated, substituted derivatives are ricinoleyl, 12-hydroxystearoyl, 2-hydroxy-3-methylbutyroyl, 3-hydroxy-2-aminopentanoyl, palmitoyl, elaidyl, eleostearoyl, arachidoyl, arachidonyl, gadoleyl, behenyl, erucyl, 8-methyldecanoyl, 9-methyldecanoyl, docosohexaenoyl or eicosapentaneoyl radicals.

Compounds of general formula I and notably mono- and bis-phosphorylated compounds referred to in code names as OM-294-MP (MP) and OM-294-DP (DP), respectively, have distinctive interesting pharmacological properties, mainly with regard to immunomodulation. They are particularly relevant in the treatment of diseases related to a deficiency in the immune defense system or an overexpression of immune responses, depending on doses being used. They find equally use in cancer therapy and as adjuvants or response enhancers in formulating vaccines.

Other applications include use as vectors for molecules of therapeutic interest due to their ability to form non covalent complexes based on hydrophilic or hydrophobic interactions. Their amphophilic character enhances formulation and transport of molecules of therapeutic interest to the membrane receptors, as well as the cell membranes and cytoplasm. They can be used alone or in conjunction with a molecule of therapeutic interest by administering them through oral, parenteral, rectal,


topical, subcutaneous or submucosal route. They can be used solely or in combination with a molecule of therapeutic interest by carrying out extemporaneous incubation *ex vivo* with blood cells in order to promote formation of immunocompetent cells before injecting them back *in vivo* using parenteral administration.

MP and DP molecules display similar properties, as adjuvants for the immune system when used for example in vaccination, in combination with the appropriate antigens, against diseases of viral, parasitic, microbial or fungal origin. In contrast, the compounds according to the invention show utterly different properties regarding their capacity to induce cytokine production or maturation of immunocompetent stem cells derived from hematopoietic and lymphoid organs.

MP compound promotes maturation and differentiation of monocytes into functional dendritic cells, in presence or absence of the appropriate antigen and acts in promoting humoral and cell mediated immunity. DP compound shows, on the other hand, antitumoral properties.

The compounds in accordance with the invention are particularly interesting due to their low toxicity. They are used for treating humans and animals in doses ranging from 0.025 mg to 100 mg per unit dosage and from 0.05 to 200 mg daily.

The present invention is equally directed to a method for obtaining dipeptide-like compounds of general formula I, which comprises the steps of blocking amine functional groups in positions (q+1) and ω of diamino acid by blocking reagents which readily undergo acidolysis and hydrogenolysis, respectively, reacting the still free carboxylic functional group with a reducing agent to yield a corresponding alcohol, freeing the amine functional group in position (q+1) and then acylating by means of a carboxylic acid functional derivative of formula R_2OH , wherein R_2 is as defined above, and subsequently freeing the terminal amine functional group by hydrogenolysis to yield the diamino alcohol of general formula II




(II)

wherein R_2 designates an acyl group derived from a saturated or
 5 unsaturated, straight or branched chain-carboxylic acid having from 2 to 24
 carbon atoms, which is unsubstituted or bears one or more substituents as
 defined above,

p and q each designate an integer ranging from 1 to 10,

which amino alcohol is condensed in presence of a peptide
 10 condensing agent in an inert solvent, together with a ω -hydroxy, ω -amino or
 ω -thio amino acid compound of general formula III



(III)


wherein R_1 designates an acyl group derived from a saturated or
 15 unsaturated, straight or branched chain-carboxylic acid having from 2 to 24
 carbon atoms, which is unsubstituted or bears one or more substituents as
 defined above

m is an integer ranging from 1 to 10,

20 and n is an integer ranging from 0 to 10,

and X is an acid group as specified previously which is optionally in
 an ester form

in order to produce a dipeptide-like compound of general formula IV




25

(IV)

wherein substituents R_1 , R_2 , and subscripts n , m , p and q have the
 same meanings as specified above,


the terminal free alcohol functional group of which can be - if necessary - alkyl or acyl or otherwise substituted by an alkyl or acyl or an otherwise substitution reagent, if needed, in presence of a coupling agent, and subjected to a catalytic hydrogenation or some other deprotection treatment in order to obtain the derivative of general formula I



(I)

wherein A, B, as well as substituents and subscripts X, Y, R₁, R₂, n, m, p and q have the same meanings as those given above.

The invention is also directed to a method for obtaining phosphodipeptide-like compounds of general formula I'



(I')


wherein R₁ and R₂ each designate an acyl group derived from a saturated or unsaturated, straight or branched chain-carboxylic acid having from 2 to 24 carbon atoms, which is unsubstituted or bears one or more substituents selected from the group comprises of hydroxyl, alkyl, alkoxy, acyloxy, amino, acylamino, acylthio and ((C₁₋₂₄)alkyl)thio groups,

subscripts m, p and q are integers ranging from 1 to 10,

subscript n is an integer ranging from 0 to 10,

X and Y each designate a hydrogen atom or a phosphono group, which consists in blocking amine functional groups in positions (q+1) and ω of a diamino acid of formula H₂N(CH₂)_pCHNH₂(CH₂)_{q+1}COOH by blocking reagents which readily undergo acidolysis and hydrogenolysis, respectively, reacting the still free carboxylic functional group with a reducing agent to yield a corresponding alcohol, freeing the amine functional group in position (q+1) and then acylating by means of a

carboxylic acid functional derivative of formula R_2OH wherein R_2 is as defined above, then freeing the terminal amine functional group by hydrogenolysis to obtain an amino alcohol of general formula II



5

(II)


wherein R_2 designates an acyl group derived from a saturated or unsaturated, straight or branched chain-carboxylic acid having from 2 to 24 carbon atoms, which is unsubstituted or bears one or more substituents as specified above,

10

p and q designate an integer ranging from 1 to 10

which amino alcohol is condensed in presence of a peptide condensing agent in an inert solvent, together with an ω -hydroxy amino acid functional derivative of general formula III' :

15



(III')

wherein R_1 is an acyl group derived from a saturated or unsaturated, straight or branched chain-carboxylic acid having from 2 to 24 carbon atoms, which is unsubstituted or bears one or more substituents,


20

m is an integer ranging from 1 to 10,


n is an integer ranging from 0 to 10,

and X is dialkyloxy- or diaryloxy- phosphoryl radical of formula

25




to yield the peptide-like compound of general formula IV'



(IV')

wherein substituents R_1 , R_2 , and subscripts m , n , p and q are as defined above, and R is a radical which readily undergoes hydrogenolysis, the other alcohol functional group of which can be - if desired - phosphorylated by a phosphorylating agent in presence of a coupling agent, if needed, and subjected to a catalytic hydrogenation on one hand in order to unblock the alcohol functional group optionally present on acyl group R_2 and on the other, free the phosphate functional group and then unblock through hydrogenolysis the second optionally present phosphate functional group, in order to obtain the derivative of general formula V



(V)

wherein Y designates either a hydrogen atom or a phosphono group, and optionally performing the further step of salt formation by means of an organic or mineral base.

Stereochemistry of chiral centers of acylamino groups is determined by initially used amino acid configuration whereas stereochemistry of acylamino groups depends on initially used fatty acid configuration. One can start from a diamino acid having L or D configuration or of a racemic nature. One can start from a hydroxylated amino acid of L, D configuration or of a racemic mixture. All such stereoisomers or diastereoisomers are included in the scope of the invention.

The method according to the invention can still further be defined by the following currently preferred operating procedures which are outlined in reaction schemes 1, 2 and 3 (Figures 33, 34 and 35) :

1. Blocking the amine functional group in position ω of the ornithine derivative chain is accomplished by N-benzyloxycarbonyl substitution after initially reacting the acid functional group with a copper salt, in alkaline medium, reacting this copper carboxylate with benzyl chloroformate and freeing the carboxylic functional group by chelating copper in an acid environment, in order to obtain an N-benzyloxycarbonyl-substituted derivative, according to the method disclosed in "Organic Preparations and Procedures International, 23 (1992) : 191 - 194".

2. Blocking the amine functional group in position α of the ornithine derivative carboxyl moiety is performed by tertbutyloxycarbonyl substitution by means of an alkyl pyrocarbonate such as tertbutyl pyrocarbonate in alkaline medium.

Terbutyl pyrocarbonate reacts with the proximal amine functional group to give the ω -benzyloxycarbonylamino α -tertbutylcarbonylamino carboxylic derivative.

3. Conversion of the carboxylic functional group into a primary alcohol functional group is effected according to the method disclosed in Tetrahedron Letters, 32 (1991) 923 - 926 which consists in reacting the carboxylic derivative with an alkyl chloroformate, such as isobutyl chloroformate, to form a mixed anhydride which is reduced by means of an alkaline or an alkali-earth metal borohydride, to finally yield the corresponding hydroxylated derivative, having a primary alcohol functional group.

4. Removal of the tertbutyloxycarbonyl group in position α is performed using trifluoroacetic acid which at the same time allows the formation of an amine functional group corresponding trifluoroacetate.

5. Acylation of the thus freed amine functional group is accomplished starting from a trifluoroacetic salt by means of a mixed anhydride prepared from R_2OH acid and an alkyl chloroformate.

6. Freeing of the terminal amine functional group is accomplished by hydrogenolysis in presence of a noble metal-based catalyst such as platinum, palladium on a carbon or iridium support material.

7. Peptide coupling or linkage between the amino compound of formula II and the phosphoryl derivative of formula III' is accomplished in presence of a coupling agent such as 1-isobutyloxy-2-isobutyloxycarbonyl-

1, 2-dihydroquinoline in an inert solvent such as a halogen-containing solvent, or in presence of a carbodiimide.

Hence, there is obtained a dipeptide-like compound of general formula (IV') the hydroxyl functional group of which optionally born by the acyl group R_2 is blocked.

8. Freeing of the hydroxyl functional group of the acyl group R_2 involves hydrogenolysis in presence of a noble metal such as palladium, applied on a substrate like carbon.

9. Freeing of the phosphoric group is accomplished by catalytic hydrogenation in presence of a noble metal oxide such as platinum oxide.

10. Phosphorylation of the dipeptide-like derivative IV' is accomplished in a two-step process (Helv. Chim. Acta, 70 (1987), 175) During the first step, compound IV' is reacted with a dialkyl or diaryl- N, N-dialkyl phosphoramidite, in presence of a coupling agent such as [1H]-tetrazole in a polar solvent such as tetrahydrofurane; the phosphite thus formed is then oxidized into a phosphate by means of an aromatic peroxy-carboxylic acid such as for instance peroxyphthalic acid, m-chloroperbenzoic acid or nitroperbenzoic acid. Freeing of the phosphoric group Y (formula V) is done by catalytic hydrogenation in presence of a noble metal such as palladium impregnated on carbon.

11. Phosphorylation of the homoserine derivative is effected by means of a diphenylphosphoryl halide in presence of pyridine and N, N-dialkylaminopyridine (Helv. Chim. Acta, 58 : (1975), 518), after blocking the amine functional group by tertbutoxycarbonyl substitution by means of tertbutyl pyrocarbonate in alkaline medium and blocking the carboxylic functional group following the formation of a cesium salt, and benzylation by means of a benzyl halide in dimethylformamide or dimethylacetamide.

12. Acylating the nitrogen atom of the homoserine derivative is accomplished by deprotecting the amine functional group by trifluoroacetic acid to obtain the amine trifluoroacetic salt, and reacting with the mixed anhydride resulting from the reaction between the carboxylic acid R_1OH and an alkyl chloroformate in presence of a reactive amine such as N-methylmorpholin.

The invention further relates to intermediates of general formula II and general formulae III and III', either in the form of a pure enantiomer or a mixture of stereoisomers.

5 The invention still relates to pharmaceutical compositions containing as an active ingredient at least one compound of general formula I, either in neutral or charged form, in combination or in admixture with a non toxic, pharmaceutically acceptable, inert excipient or carrier.

10 The invention relates more specifically to pharmaceutical compositions containing as an active ingredient at least one salt of a compound of general formula I, together with an organic or mineral base intended for therapeutic use.

15 The invention still further relates to pharmaceutical compositions based on a compound of general formula I, either in the form of a pure enantiomer or in the form of a mixture of stereoisomers, in combination or in admixture with a pharmaceutical excipient or carrier.

20 Among pharmaceutical formulations herein contemplated, mention should be made of those which are suitable to administration by mucosal, transcutaneous, topical, parenteral, digestive route or inhalation such as for instance coated or uncoated tablets, capsules, injection solutes or suspensions, spray, gels, plasters or rapid absorption solutes.

In preference, the compounds of the invention are administered by injection as aqueous solutions or suspensions, optionally neutralized by an amine or a hydroxyalkylamine.

25 The following non limiting examples further illustrate the invention. They are outlined in reaction schemes 1 to 6 (Figures 33 - 38).

EXAMPLE I

4-(diphenyloxyphosphoryloxy)-2-[(R)3-dodecanoyloxytetradecanoylamino]butanoic acid

1. N α -Terbutyloxycarbonyl-DL-homoserine

30 2 g of homoserine (16.78 mmol) were dissolved in 20 ml of water and to the solution 16.78 ml of 1 M NaOH and 3.006 g of cesium carbonate (9.23 mmol) were added. After stirring for 5 minutes, the solution was cooled in an ice/water bath. 60 ml of dioxane and terbutyl pyrocarbonate were then added. The reaction mixture was kept under stirring in an ice-cold water bath for 1 hour and thereafter at room temperature for 5 hours.

35

The solvent was subsequently removed under vacuum. The dry residue was directly used in the next step.

2. N α -Terbutyloxycarbonyl- benzyl-DL- homoserinate

To the residue of step 1, 20 ml of dimethylformamide were added and the solvent was evaporated to dryness then to the reaction mixture were added 60 ml of dimethylformamide and 4.5 ml of benzyl bromide (20.13 mmol). At this point, a white precipitate formed. The mixture was kept under stirring for 16 hours. The solvent was then driven away under vacuum. The residue was depleted or extracted twice with 20 ml of ethyl acetate. The organic layer was respectively washed with water (20 ml) and with brine (20 ml), then dried on anhydrous magnesium sulfate. The solvent was evaporated and the residue was used as such in the next step.

3. benzyl N α -Terbutyloxycarbonyl- O-(diphenyloxyphosphoryl)-DL- homoserinate

The residue of the previous step was dried under high vacuum then dissolved in methylene chloride (60 ml). 4,11 g of 4-dimethylaminopyridine (33.56 mmol) were then added to the solution, the reaction mixture was stirred for 10 minutes, and 12 ml of pyridine and 6.95 ml of chlorophosphate (33.56 mmol) were then added. The solution was stirred at room temperature for 18 hours then washed with 1N hydrochloric acid (5 x 20 ml), water (30 ml) and brine (30 ml). The organic layer was dried over anhydrous magnesium sulfate and the solvent was driven away under vacuum. The residue was purified by flash chromatography (hexane/ethyl acetate = 4:1). The main fraction was concentrated to cristallize the residue. As a result, there was obtained 7,49 g of phosphorylated product, that is a yield of 82.4%. Melting point : 63.5 - 64.0°C.

4. Benzyl O-(diphenyloxyphosphoryl)-DL-homoserinate

The phosphorylated product of the previous step (7.88 g i.e 15.4 mmol) was dissolved in 15 ml of trifluoroacetic acid and the solution was kept under stirring at room temperature for 2.5 hours. The solvent was then driven away under vacuum, the residue was purified by flash chromatography (MeOH / CH₂Cl₂ = 10:1). The main fraction was concentrated and the residue was cristallized at room temperature. As a result, 7,17 g of phosphorylated product were recovered (88,9% yield). This was used in the next step with no further work-up.

5. Benzyl 2-[(R)-3-Dodecanoyloxytetradecanoylamino]-4-(diphenyloxyphosphoryloxy)butanoate

4.284 g (10.07 mmol) of (R) 3-dodecanoyloxytetradecanoic acid prepared according to the method disclosed in Bull. Chem. Soc. Jpn., 60 (1987), 2205 - 2214, were dissolved in 30 ml of tetrahydrofuran and the solution was cooled down to -15°C in an ice-cold brine bath. 1,108 ml (10.07 mmol) of N-methylmorpholin and 1.31 ml (10.07 mmol) of isobutyl chloroformate were then added. Stirring was continued for 30 minutes. To the reaction mixture, there was added 5.724 g (10.07 mmol) of benzyl O-(diphenyloxyphosphoryl)-DL-homoserinate in a mixture of 30 ml of tetrahydrofuran and 5 ml of triethylamine. After stirring overnight at room temperature, the solvent was driven away under vacuum and 20 ml of water were added to the residue. The mixture was then extracted with ethyl acetate (2 x 30 ml). The organic layers were pooled, washed in succession with water (20 ml) and brine (20 ml) and dried over magnesium sulfate. The solvent was evaporated and the residue was purified by flash chromatography (hexane - ethyl acetate 2 : 1, R_f = 0.29); yield 7.455 g i.e. 87.1% m.p. 31.0° - 32.1°C, $^1\text{H-NMR}$ (CDCl_3 , 250 MHz), δ in ppm : 7.4 - 7.1 (m, 15H), 6.90 (2d, 1H, $^3J = 7.6$ Hz, NH), 5.3 - 5.1 (m, 3H), 4.7 (m, 1H), 4.35 (m, 2H), 2.45 (m, 2H), 2.4 - 2.1 (m, 4H), 1.6 (m, 4H), 1.4 - 1.1 (m, 34H), 0.9 (t, 6H). $^{13}\text{C-NMR}$ (CDCl_3 , 63 MHz), δ in ppm : 173.01, 171.08, 169.66, 150.18, (d, $^2J_{\text{P,C}} = 7.1$ Hz), 135.01, 129.60, 128.33, 128.14, 127.96, 125.21, 119.80 (d, $^3J_{\text{P,C}} = 5.0$ Hz), 70.69, 67.05, 65.19 (d, $^2J_{\text{P,C}} = 5.6$ Hz), 49.13, 40.97, 40.77 (2 diast.), 34.20, 33.98, 33.82, 31.70, 29.42, 29.34, 29.14, 28.94, 25.01, 24.47, 13.91.

6. 4-(diphenyloxyphosphoryloxy)-2-[(R)-3-dodecanoyloxytetradecanoylamino]-butanoic acid

A solution was prepared from the benzyl ester obtained in step 5 (2.23 g i.e. 2.6 mmol) in 300 ml of HPLC-grade methanol in a three neck-round flask and then 1.0 g of carbon- 10% palladium was added. Air contained in the round flask was discharged under vacuum, and the flask was loaded with hydrogen gas under atmospheric pressure.

The reaction mixture was stirred at room temperature for 1 hour, the catalyst was then quickly filtered off on a membrane and the filtrate was concentrated to obtain a colorless liquor. This product was homogeneous

as assessed by thin layer chromatography and NMR, and was used directly with no further purification treatment in the coupling step; $R_f = 0.75$ (dichloromethane - methanol - triethylamine, 10 : 1 : 0.5). ^1H -RMN (CDCl_3 , 250 MHz), δ in ppm : 7.4 - 7.1 (m, 10H), 6.85 (2d, 1H, NH), 5.15 (m, 1H), 4.6 (m, 1H), 4.35 (m, 2H), 2.45 (m, 2H), 2.4 - 2.15 (m, 4H), 1.6 (m, 4H), 1.4 - 1.1 (m, 34H), 0.9 (t, 6H). ^{13}C -NMR (CDCl_3 , 63 MHz), δ in ppm : 173.35, 171.30 (2 diast.), 172.75, 170.37, 150.0 (d, $^2J_{\text{P,C}} = 7.5$ Hz), 129.55, 125.28, 119.71 (d, $^3J_{\text{P,C}} = 4.4$ Hz), 70.78, 65.65, (d, $^2J_{\text{P,C}} = 5.9$ Hz), 49.00, 40.77, 40.63 (2 diast.), 34.13, 33.86, 33.76, 31.59, 29.31, 29.25, 29.03, 28.82, 24.88, 24.68, 22.36, 13.76.

The 4-(diphenyloxyphosphoryloxy)-2-[(R)-3-benzyloxytetradecanoylamino]-butanoic acid can be prepared using the same reaction scheme by replacing in step 5 of example I, (R)-3-dodecanoyloxytetradecanoic acid by (R)-3-benzyloxytetradecanoic acid.

EXAMPLE II

(2R)-5-amino-2-[(R)-3-benzyloxytetradecanoylamino]-pentan-1-ol

1. Copper salt of D-ornithine

To a solution of D-ornithine (5.25 g i.e. 30 mmol) in 30 ml of 1M sodium hydroxide, 50 ml of a solution of cupric sulfate pentahydrate (3.814 g i.e. 15.3 mmol) in water were added. Stirring was continued for 2 hours. The solvent was evaporated to dryness. 60 ml of methanol were added to form a purple-colored solid which was separated, washed with dioxane and methanol, respectively.

2. copper (2R)-5-Amino-5-benzyloxycarbonylamino) pentanoate

The purple-colored solid was dissolved in 40 ml of 1M soda lye and 70 ml of dioxane, the solution was cooled in an ice-cold water bath and 5.14 ml (i.e. 36 mmol) of benzyl chloroformate were added. Stirring was continued in an ice-cold water bath for 3 hours and thereafter at room temperature for 15 hours. The purple precipitate was collected and washed with 95% ethanol (40 ml), with water (50 ml) and with ethanol (60 ml), respectively. The precipitate was dried in an oven ($T < 45^\circ\text{C}$, under vacuum); the yield of the two-step process was 8.27 g, i.e. 93% of the predicted yield.

3. (2R)-5-(benzyloxycarbonylamino)-2-(terbutyloxycarbonylamino)pentanoic acid

The copper salt obtained in step 2 was dissolved in 2M hydrochloric acid (400 ml) and EDTA was added (8.15 g, 27.8 mmol) thereto. The mixture was stirred for 2.5 hours, and neutralized to pH 7 by adding soda lye (about 160 ml). A white precipitate was formed. The mixture was stirred for 2.5 hours in an ice-cold water bath. The precipitate was filtered, washed with cold water until washing effluents were colorless, then dried in an oven under 60°C. This solid was dissolved in 156 ml of 1M NaOH and the solution was cooled with an ice-cold water bath. To this solution, 7.7 g (35.2 mmol) of tert-butyl pyrocarbonate in dioxane (160 ml) were added. The mixture was stirred at 0°C for 45 minutes then for 16 hours at room temperature. The organic solvent was evaporated and 70 ml of ethyl acetate were added to the residue. The aqueous layer was acidified by adding 2N hydrochloric acid down to pH \approx 3. The aqueous layer was extracted once again with 100 ml of ethyl acetate. The organic layers were combined and washed with water (30 ml) and with brine (30 ml). The solvent was removed under vacuum to thereby provide a colorless oil after flash chromatography purification (yield : 8.42 g in 2 steps i.e. 76.7% of the predicted yield) (R_f = 0.19, dichloroethane - MeOH 20 : 1).

4. (2R)-5-(Benzyloxycarbonylamino)-2-(terbutyloxycarbonylamino)pentan-1ol

To a cold solution (-15°C) of the diamino pentanoic acid derivative obtained in step 3 (5.45 g i.e. 14.8 mmol) in 60 ml of THF, 1.654 ml (i.e. 14.8 mmol) of N-methylmorpholin and 9.6 ml (i.e. 14.8 mmol) of isobutyl chloroformate (IBCF) were added. The solution was stirred at -15°C for 1 minute followed by addition of sodium borohydride (5.104 g i.e. 44.6 mmol) in 10 ml of water. The stirring was conducted at -15°C for further 10 minutes then 400 ml of water were added to stop the reaction. The solution was extracted with ethyl acetate (100 ml x 2). The organic layers were combined and washed with 50 ml of water and with 60 ml of brine then dried over anhydrous magnesium sulfate. The solvent was removed and the residue recrystallized from an ethyl acetate/hexane mixture (4.95 g, 94.9% yield) m.p. 47.5 - 48°C.

5. Unblocking of the 2,5-diaminopentan-1-ol derivative

6.32 g (18 mmol) of (2R)-5-(benzyloxycarbonylamino)-2-(terbutyloxycarbonylamino)-pentan-1-ol obtained in step 4 were dissolved in 25 ml of trifluoroacetic acid followed by stirring the solution for 2.5 hours at room temperature. The solvent was then evaporated and the residue was purified by running flash chromatography (MeOH/CH₂Cl₂ = 10 : 1). A colorless vitreous bulk product was obtained as a result which melts at room temperature. Yield was 5.45 g in terms of trifluoroacetic salt (yield = 82.7%). The hydrochloride compound melts at 133.0° - 134.3°C (recrystallization from methanol).

6. (2R)-5-(Benzyloxycarbonylamino)-2-[(R)-3-benzyloxytetradecanoylamino]pentan-1-ol

To a previously cooled solution to -15°C, 5.27 g (15.8 mmol) of (R)-3-benzyloxytetradecanoic acid (Bull. Chem. Soc., Jpn., 60 (1987), 2197 - 2204) in 30 ml of tetrahydrofuran, 1.89 ml (15.8 mmol) of N-methylmorpholin and 2.21 ml of IBCF (15.8 mmol) were added. The reaction mixture was kept under stirring at -15°C for 30 minutes. Then, 5.25g of trifluoroacetate salt of the preceding example (14.4 mmol) in 30 ml of tetrahydrofuran and 1.44 ml of triethylamine were added to the solution. Stirring was continued at room temperature for 16 hours then 30 ml of water and 60 ml of ethyl acetate were added; the organic layer was separated and the aqueous layer was extracted once again with ethyl acetate (60 ml). The organic layers were pooled and washed with water (30 ml) and with brine (30 ml) then dried over anhydrous magnesium sulfate. The solvent was evaporated and the residue was recrystallized from an ethyl acetate/hexane mixture (5.842 g, i.e. 71.2% yield), m.p. = 117.5 - 118°C. R_f = 0.32, ethyl acetate - petroleum ether 3 : 1. ¹H-NMR (CDCl₃, 250 MHz), δ in ppm : 7.4 - 7.2 (m, 10H), 6.5 (2d, 1H, NH), 5.1 (s, 2H), 4.9 (m, 1H, NH), 4.5 (2d, AB, 2H), 3.8 (m, 2H), 3.5 (m, 2H), 3.1 (m, 2H), 2.4 (m, 2H), 2.4 (m, 2H), 1.6-1.4 (m, 6H), 1.4-1.2 (m, 18H), 0.9 (t, 3H). ¹³C-NMR (CDCl₃, 63 MHz), δ in ppm : 172.24, 156.49, 138.06, 136.53, 128.46, 128.04, 127.87, 76.76, 71.39, 66.60, 65.44, 51.54, 41.43, 40.65, 33.76, 31.87, 29.61, 29.30, 28.01, 26.47, 25.05, 22.65, 14.09.

7. (2R)-5-Amino-2-[(R)-3-benzyloxytetradecanoylamino]pentan-1-ol

In a three neck-flask, 150 mg of 20% palladium/carbon were added to the solution of (2R)-5-(Benzyloxycarbonylamino)-2-[(R)-3-benzyloxytetradecanoylamino]pentan-1-ol (3.0 g, i.e. 5.27 mmol) and 6 ml of triethylamine in 300 ml of HPLC-grade ethanol. Air was discharged under vacuum then the flask was loaded with hydrogen. The reaction mixture was stirred at room temperature for 2 hours then the catalyst was filtered off by membrane filtration and the filtrate was concentrated to provide a homogenous white solid as shown by TLC, to be used as such in the next step with no further purification, $R_f = 0.2$, dichloromethane - methanol - triethylamine 5 : 10.5, m.p. = 47 - 48°C.

$^1\text{H-NMR}$ (CDCl_3 , 250 MHz), δ in ppm : 7.4 - 7.2 (m, 5H), 6.75 (d, 1H, NH) 4.5 (2d, AB, 2H), 3.9 (m, 2H), 3.5 (m, 2H), 2.3 - 2.6 (m, 7H), 1.7 - 1.2 (m, 24H), 0.9 (t, 3H). $^{13}\text{C-NMR}$ (CDCl_3 , 63 MHz), δ in ppm : 171.86, 138.13, 128.37, 127.87, 127.75, 76.81, 71.50, 64.57, 51.38, 41.51, 41.17, 33.89, 31.82, 29.26, 28.57, 28.03, 25.07, 22.60, 14.04.

(2R)-5-amino-2-[(R)-3-dodecanoyloxytetradecanoylamino]pentan-1-ol can be obtained according to the same reaction scheme by replacing in step 6 of example II, (R)-3-benzyloxytetradecanoic acid by (R)-3-dodecanoyloxytetradecanoic acid.

EXAMPLE III

3-[(R)-3-dodecanoyloxytetradecanoylamino]-4-oxo-5-aza-9-[(R)-3-hydroxytetradecanoylamino]-decane-1, 10-diol 1-dihydrogenphosphate.

1. Peptide Coupling

In a solution of (2RS)-4-(diphenyloxyphosphoryloxy)-2-[(R)-3-dodecanoyloxytetradecanoylamino]butanoic acid (1.0 mmol) as obtained in Example I, dissolved in 20 ml of methylene chloride, 363.6 mg (1.2 mmol) of IDQ (1-isobutyloxy-2-isobutyloxycarbonyl-1, 2-dihydroquinoline) are suspended. After stirring for 15 minutes, addition is made of 1.0 mmol of (2R)-5-amino-2-[(R)-benzyloxytetradecanoylamino]pentan-1-ol from Example II, being dissolved in 10 ml of methylene chloride and the reaction mixture is kept under stirring for 4 hr.

The solution is concentrated and the residue is purified by a flash chromatography treatment ($\text{CH}_2\text{Cl}_2/\text{acetone} = 5 : 2$, $R_f 0.23$). The solvent is removed thus obtaining a colorless thick liquor (0.620 g i.e. 52.7% yield) of

a phosphorylated dipeptide-like compound. $R_f = 0.49$, dichloromethane - methanol - triethylamine, 10 : 1 : 0.5. $^1\text{H-NMR}$ (CDCl_3 , 250 MHz), δ in ppm : 7.40 - 7.15 (m, 15), 7.00 (m, 1H), 6.90 and 6.80 (2d, 2 diast., 1H), 6.65 (d, 1H) (3 x NH), 5.15 (m, 1H), 4.50 (m, 3H), 4.30 (m, 2H), 3.85 (m, 2H), 3.45 (m, 2H), 3.15 (m, 2H), 2.41 - 2.14 (m, 8H), 1.6 - 1.4 (m, 8H), 1.4 - 1.1 (m, 54H), 0.9 (t, 9H, 3 CH_3). $^{13}\text{C-NMR}$ (CDCl_3 , 63 MHz), δ in ppm : 173.11, 171.68, 170.52 (2 diast.), 169.94 (2 diast), 150.0 (d, $J_{\text{PC}} = 7.2$ Hz), 138.0 (2 diast.), 129.58, 127.99, 127.49, 127.26, 125.24, 119.73 (t, $J_{\text{PC}} = 5.0$ Hz), 76.48, 71.12, 70.71, 65.86 (broad spin), 64.22, 50.96, 49.71 (broad spin), 41.46, 41.05, 39.07, 34.13, 34.00, 32.70, 31.61, 29.34, 29.06, 28.87, 27.98, 25.25, 24.92, 24.72, 22.38, 13.80.

2. 1-(Diphenyloxyphosphoryloxy)-3-[(R)-3-dodecanoyloxytetradecanoylamino]-4-oxo-5-aza-9-[(R)-3-hydroxytetradecanoylamino]decan-10-ol

The phosphorylated dipeptide-like compound solution (488 mg i.e. 0.42 mmol) obtained above and acetic acid (1.9 ml) in 65 ml of HPLC-grade ethanol were introduced in a three-neck round flask and 200 mg of palladium on carbon containing 10% Pd were added. Air was discharged under vacuum and the flask was loaded with hydrogen. The reaction mixture was stirred at room temperature for 2 hr., then the catalyst was filtered off by membrane filtration, the solvent was driven away under vacuum, to thereby recover the crude product with a yield of 92%. A sample of the product was purified by flash chromatography (CH_2Cl_2 /acetone 5:4, $R_f = 0.24$). As a result, a glass-like solid was obtained. $R_f = 0.68$, 5 : 2 methylene chloride - methanol. ($^{13}\text{C-NMR}$ (CDCl_3 , 63 MHz), δ in ppm (a few signals in doublet form due to the presence of diastereoisomers were observed): 173.60, 173.15, 170.67, 170.60, 170.27, 170.07, 150.24 (d), 129.92, 125.66, 120.05, 119.90 (2d), 71.11, 71.05, 68.83; 66.21 (broad spin), 64.71, 51.38; 50.32, 50.12, 43.25, 43.12, 41.66, 41.57, 39.30, 37.26, 34.45, 32.84, 31.86, 29.62, 29.5, 29.29, 29.13, 28.08, 25.57, 25.19, 24.97, 22.62, 14.03.

3. 3-[(R)-3-Dodecanoyloxytetradecanoylamino-4-oxo-5-aza-9-[(R)-3-hydroxytetradecanoylamino]decan-1, 10-diol 1-dihydrogenphosphate

In a three-neck round flask, platinum oxide (137 mg) was preactivated with hydrogen in absolute ethanol (5 ml) for 10 min. Addition

was then made of a solution of 1-(diphenyloxyphosphoryloxy)-3-[(R)-3-dodecanoyloxytetradecanoylamino]-4-oxo-5-aza-9-[(R)-3-hydroxytetradecanoylamino]decan-10-ol (411 mg i.e. 0.38 mmol) in absolute ethanol (20 ml). Air was discharged under high vacuum, and the flask was then loaded with hydrogen. The reaction mixture was stirred at room temperature for 2 - 3 hr., the catalyst was filtered off by membrane filtration, and finally the solvent was driven away under vacuum. As a result, a crude product in the form of a white solid was finally obtained. (crude product yield : 98%). R_f = 0.50, chloroform - methanol - water, 6:4:0.6.

3-[(R)-3-hydroxytetradecanoylamino]-4-oxo-5-aza-9-[(R)-3-dodecanoyloxytetradecanoylamino]-decan-1, 10-diol 1-dihydrogenphosphate can be obtained starting from 4-(diphenyloxyphosphoryloxy)-2-[(R)-3-benzyloxytetradecanoylamino]butanoic acid and (2R)-5-amino-2-[(R)-3-dodecanoyloxytetradecanoylamino]pentan-1-ol according to the same reaction scheme (scheme 3) (Figure 35).

Alternatively, 3-[(R)-3-dodecanoyloxytetradecanoylamino]-4-oxo-5-aza-9-[(R)-3-hydroxytetradecanoylamino]-decan-1, 10-diol 1-dihydrogenphosphate is obtained starting from aspartic acid according to the following reaction scheme (reaction schemes 1, 5 and 6) (Figures 33, 37 and 38): protecting the free OH functional group of (2R)-5-(benzyloxycarbonylamino)-2-[(R)-3-benzyloxytetradecanoylamino]pentan-1-ol by a benzyloxymethyl group, freeing the 5-amino functional group of this compound by hydrogenolysis, effecting peptide coupling of this amine with a monoesterified derivative of D or L-aspartic acid bearing at the amine functionality thereof either a protecting group or an (R)-3-dodecanoyloxytetradecanoyl group, freeing and reducing the terminal carboxylic functional group by means of a mixed anhydride, deprotecting, if needed, the amine functional group derived from aspartic acid then N-acylating with an (R)-3-dodecanoyloxytetradecanoic acid derivative, phosphorylating the hydroxy functional group at C₁ and finally unblocking the phosphate and hydroxyl functional groups through hydrogenolysis.

EXAMPLE IV

Preparation of 3-[(R)-3-dodecanoyloxytetradecanoylamino]-4-oxo-5-
aza-9-[(R)-3-hydroxytetradecanoylamino]decan-1, 10-diol 1, 10-
bis(dihydrogenphosphate)

5

1-(diphenyloxyphosphoryloxy)-3-[(R)-3-dodecanoyloxytetradecanoylamino]-
4-oxo-5-aza-9-[(R)-3-benzyloxytetradecanoylamino]decan-10-ol (985 mg
i.e. 0.84 mmol) is reacted with dibenzyl N, N'-diethylphosphoramidite (0.58
ml, 85% pure), in presence of [1H]-tetrazole (182 mg) in tetrahydrofuran
10 (35 ml) for 30 minutes at room temperature. The phosphite intermediate is
oxidized by addition of a solution of m-chloroperoxybenzoic acid (535 mg)
in 25 ml of methylene chloride at a temperature range of 0° to -20°C. After
20 min., a solution of Na₂S₂O₃ (20 ml) is added to neutralize any excess
oxydant, then the organic layer is diluted with ether. The organic layer is
15 separated, washed in succession with an aqueous solution of Na₂S₂O₃ (5 x
20 ml), then a solution of NaHCO₃ (2 x 20 ml), thereafter with aqueous
hydrochloric acid (20 ml), dried over MgSO₄ and concentrated. The crude
product is purified by flash chromatography treatment over a silica gel
(CH₂Cl₂ - acetone 10 : 3). The protected diphosphorylated derivative thus
20 obtained (900 mg, 75% yield) (R_f 0.64, 5 : 2 dichloromethane - acetone) is
subjected to a catalytic hydrogenation in HPLC-grade methanol (1000 ml)
in presence of 10% palladium - carbon (300 mg) under atmospheric
pressure, for 4 hr. at room temperature. The catalyst is filtered off by
membrane filtration and the filtrate is concentrated under reduced
25 pressure, to thereby recover crude 10-(dihydroxyphosphoryloxy)-1-
(diphenyloxyphosphoryloxy)-3-[(R)-3-dodecanoyloxytetradecanoylamino]-4-
oxo-5-aza-[(R)-3-hydroxytetradecanoylamino]decane (R_f = 0.63,
chloroform -methanol-water 6 : 4 : 0.6) with a yield of 89%. This product is
then submitted to a catalytic hydrogenation on platinum oxide (380 mg) in
30 HPLC-grade ethanol (130 ml) for 24 hr. at room temperature, under
atmospheric pressure. The catalyst is filtered off by membrane filtration and
the filtrate is concentrated to thereby obtain the free bis
dihydrogenophosphate compound (R_f = 0.20, chloroform- MeOH - water, 6
: 4 : 0.6).

3-[(R)-3-hydroxytetradecanoylamino]-4-oxo-5-aza-9-[(R)-3-dodecanoyloxytetradecanoylamino]-decan-1, 10-diol 1,10-bis(dihydrogenphosphate) can be obtained starting from 4-(diphenyloxyphosphoryloxy)-2-[(R)-benzyloxytetradecanoylamino]butanoic acid and (2R)-5-amino-2-[(R)-3-dodecanoyloxytetradecanoylamino]pentan-1-ol according to the same reaction scheme (scheme 3) (Figure 35).

Alternatively, 3-[(R)-3-dodecanoyloxytetradecanoylamino]-4-oxo-5-aza-9-[(R)-3-hydroxytetradecanoylamino]decan-1, 10-diol 1, 10-bis(dihydrogenphosphate) is obtained starting from aspartic acid using the following reaction scheme (reaction schemes 1, 4 and 6): freeing the 5-amino functional group of (2R)-5-(benzyloxycarbonylamino)-2-[(R)-3-benzyloxytetradecanoylamino]pentan-1-ol by hydrogenolysis, performing peptide coupling of this amine with a monoesterified derivative of D or L-aspartic acid bearing at the amine functionality thereof either a protecting group or a (R)-3-dodecanoyloxytetradecanoyl group, freeing and reducing the terminal carboxylic functional group by means of a mixed anhydride, deprotecting, if needed, the amine functional group derived from aspartic acid then N-acylating with an (R)-3-dodecanoyloxytetradecanoic acid derivative, phosphorylating the hydroxy functional group at C₁ and C₁₀ and finally unblocking the phosphate and hydroxyl functional groups through hydrogenolysis.

EXAMPLE V - PURIFICATION AND ANALYSIS OF COMPOUNDS ACCORDING TO THE INVENTION

1. Purification of monophosphorylated and diphosphorylated compounds

The monophosphorylated and diphosphorylated synthetic products were dissolved in a water-isopropanol mixture (1 : 1 vol./vol.) with 0.1% triethylamine to adjust the pH in the range of 8 to 9. The required amount of 2 M ammonium bicarbonate was subsequently added to achieve a concentration of 25 mM.

The purification was run by preparative reverse phase HPLC under the following conditions :

Column : Bondapack C18 Prep Pak, 40 x 200 mm, 15 - 20 μ m, 300 Å, Waters

Mobile phase :

A : isopropanol - water (1 :1, vol./vol.), 50 mM ammonium bicarbonate

B : isopropanol - water (2 :8, vol./vol.), 50 mM ammonium bicarbonate

Flow rate : 40 ml/min.

Elution : Isocratic adsorption onto column : 40% B (60% A), 10 minutes.

A : B gradient : 40 - 80% B within 10 minutes

Isocratic elution : 80% B, 30 minutes

Washing step : 100% B, 10 minutes

Detection : UV, 210 nm (wavelength)

In the aforementioned eluting conditions, the retention time of the monophosphorylated compound varies from 25 to 30 min while that for the diphosphorylated compound varies from 18 to 25 minutes. Should the presence of monophenyl-products be observed (incomplete deprotection treatment during final dephenylation), a finer purification step is required.

This further purification is performed in the following conditions :

Column : Kromasil C18, 21 x 250 mm, 5 μ m, 100 Å, Macherey - Nagel

Mobile phase :

A : isopropanol - water (1:1 - v/v), 50 mM ammonium bicarbonate.

B : isopropanol - water (2 :8, v/v), 50 mM ammonium bicarbonate

Flow rate : 10 ml/min.

Elution : Isocratic adsorption onto column : 40% B (60% A), 10 minutes

Isocratic elution :

monophosphorylated compound : 80% B, 30 minutes

diphosphorylated compound : 74% B, 30 minutes

Washing step : 100% B, 10 minutes

Detection : UV; 210 and 254 nm (wavelength)

Fractions containing the monophosphorylated or diphosphorylated compounds in the form of an ammonium salt are collected and

concentrated by adsorption on C18 phase Bondapack, 15 - 20 μm , 300 Å, Waters, The sodium salt of monophosphorylated or diphosphorylated compounds is obtained through washing with a 10g/l NaCl solution in water-isopropanol (9:1, v :v). After removal of excess NaCl by flowing over
 5 the column 5 volumes of a water - isopropanol mixture (9 :1, v/v), the compound is eluted with pure isopropanol. This solvent is then evaporated to dryness on a Rotavapor. Final dissolution is conducted with the required volume of water (with adjunction of 0,1% triethanolamine in case of a monophosphorylated compound) to achieve a target concentration of 2
 10 mg/ml. Sterile filtration is then performed on a 0,2 μm filter, Express Membrane, Millipore (if volume is less than 50 ml : the Steriflip system is recommended, if volume greater than 50 ml : the Steritop system is recommended).

In handling a monophosphorylated compound, it is advisable to
 15 sonicate the solution (3 x 10 seconds) at room temperature before running sterile filtration.

2. Monitoring and yield of purification

After termination of each step, the fractions are analyzed by reverse
 phase analytic HPLC chromatography according to the following
 20 conditions :

Column : Supelcosil C18, 3 μm , 4.6 x 150 mm, 100 Å, Supelco

Mobile phase :

A : water : acetonitrile (1 : 1, v/v), 5 mM TBAP

B : water - isopropanol (1 : 9, v/v) 5 mM TBAP

25 TBAP : tetrabutylammonium phosphate

Flow rate : 1 ml/min.

Elution : A : B gradient (75 : 25 - 0 :100) within 37.5 minutes.

Detection : UV, 210 and 254 nm (wavelength)

When chromatography is conducted accordingly, the retention
 30 times observed for mono- and diphosphorylated compounds are 25.5 ± 0.5 and 20.8 ± 0.5 minutes, respectively. The purification yields achieved range from 57 to 94% for the monophosphorylated compound and from 71 to 92% for the diphosphorylated compound. 311 mg and 189 mg of mono- and diphosphorylated compounds are obtained, respectively.

3. Assay and analysis of the final product purity level

Quantitative assays and purity level analysis of the products obtained were conducted by HPLC/UV according to the chromatography operating conditions stated previously. According to such assays, the purity levels obtained for different batches of mono- and diphosphorylated compounds vary from 99 to 100%. To show the presence of inactive impurities in the UV range, LC/ES-MS analysis were conducted (electrospray type ionization, positive mode). For the latter, the (5 mM) tetrabutylammonium phosphate was replaced by (25 mM) ammonium acetate to meet the requirements of ionization at the electrospray interface.

Alternative determination methods were used to assay the final solutions. For example, quantitative analysis of total phosphates (adapted from Ames, B.N., Methods in Enzymology VII (1966), 115 - 117), amino acids (adapted from Hughes et al., J. Chromatography, 389 : (1987), 327 - 333) and acyl chains (adapted from Miller, L.T., Hewlett Packard Application Note (1984), 228 - 237) can be listed.

4. Spectroscopic analysis

4.1. Mass spectrometry

ES-MS spectra (negative and positive modes) of mono- and diphosphorylated compounds were plotted using three types of mass spectrometers. (Finnigan LCQ, ion trap; Micromass Quattro II, triple stage quadrupole; Hewlett - Packard MSD, single quadrupole). Complementary MS/MS analysis were also conducted. Spectra demonstrating the identity and purity of said products are included in the appendix.

ES-MS Spectra (positive mode)

Diphosphorylated compound :

(Micromass Quattro II : Spectrum 1; HP-MSD : Spectrum 3) (Figure 39 & 41)

At low energy level, a major pseudomolecular ion is observed at an m/z ratio of 1014.6 $[M+H]^+$. Sodium adducts at an m/z ratio of 1036.6 $[M+Na]^+$, 1058.6 $[M-H+2Na]^+$ and at 1080.5 $[M-2H+3Na]^+$ are also visible.

Depending on the degree of fragmentation, two 916.5 $[M-98+H]^+$ and 818.6 $[M-98-H]^+$ m/z fragments are observed, a fact which demonstrates the presence of two phosphoryl group on the molecule. As

depicted by spectrum 3 (Figure 41), the relative intensity of observed ions varies considerably according to the extent of energy level being applied.

Monophosphorylated compound :

(Micromass Quattro II : Spectrum 2) (Figure 40)

5 A somewhat different ionization diagram is obtained for the monophosphorylated compound due to the presence of triethanolamine (TEoA) in the solutions being analyzed. A major pseudomolecular ion is observed at an m/z ratio of 934.4 $[M+H]^+$ as well as sodium adducts $[M+H]^+$ and potassium adducts $[M+K]^+$ at an m/z ratio of 956.3 and 972.3, respectively. A second group of adducts at an m/z ratio of 1083.4 $[M+TEA+H]^+$, an m/z ratio of 1105.3 $[M+TeOH+Na]$ and an m/z ratio of 1121.3 $[M+TeOH+K]^+$ is equally visible. The presence of a phosphoryl group inside the molecule is evidenced by a fragment being detected at high energy level corresponding to an m/z ratio of 836.4 $[M-98+H]^+$.

15 ES-MS Spectra (negative mode)

Ion species observed in negative mode ES-MS spectra for mono- and diphosphorylated compounds are quite in agreement with results obtained in the positive mode.

FAB ionization analysis (positive mode) were also conducted. At low resolution level, the mono- and diphosphorylated compounds show sodium adducts $[M+Na]^+$ at 956.5 and 1036.5 m/z ratio, respectively.

At high resolution level (3-nitro benyl alcohol matrix), a peak was observed at an m/z ratio of 956.667 for the the monophosphate compound, corresponding to the expected molecular formula : $C_{49}H_{69}O_{11}N_3PNa$ (predicted mass : 956.668 amu).

For the diphosphated compound, a peak at an m/z ratio of 1036.635 was recorded, corresponding to the expected molecular formula $C_{49}H_{97}O_{14}N_3P_2Na$ (calculated mass : 1036.634 amu).

All MS analysis provided evidence of the high purity level of the obtained products.

4.2 Nuclear magnetic resonance

1H -NMR and ^{13}C -NMR spectra for mono- and diphosphorylated compounds were determined using a DPX Bruker model apparatus operating at 250.13 and 62.89 MHz , respectively, and a Varian Unity Inova system operating at 500 - 499.87 and 125.7 MHz, respectively. ^{31}P -RMN

spectra were recorded at 121.6 MHz (DPX Brucker). Spectra showing the identity and purity of these products are included in the appendix.

¹H-NMR Spectra (Spectra 4 & 5) (Figures 42 & 43)

- Monophosphorylated compound : On spectra recorded in CDCl₃ + 0.1% triethanolamine (TEoA) (Spectrum A), signals corresponding to three protons born by nitrogen atoms N(5), N(2a) and N(2b) between 7 and 9.5 ppm (see magnified view of the spectral window) were observed. Signals ascribed to H-N(2a) and H-N(2b) appear in the form of 2 doublets which show the presence of a mixture of stereoisomers. One of the diastereoisomers is observed to be prevailing (as a result of the different purification steps).

- Diphosphorylated compound : On the spectrum recorded in CDCl₃ - CD₃OD (3 : 1, v/v) (Spectrum 5), signals corresponding to H-N(5), H-N(2a) and H-N(2b) are no longer visible as a result of species exchange in presence of CD₃OD.

Additional information regarding the assignment of different signals were gained from homo- and heteronuclear correlation experiments (¹H-¹H - NMR : COSY, ¹H - ¹³C-NMR : HSQC & HMBC).

¹³C-NMR Spectra (Spectra 6 & 7) (Figures 44 & 45)

Recording of ¹³C-NMR spectra is extremely difficult to carry out due to the rather low solubility of mono- and diphosphorylated compounds.

³¹P-NMR spectra (Spectra 8 & 9) (Figures 46 & 47)

For both mono- and diphosphorylated compounds, a single peak is observed.

EXAMPLE V - PHARMACOLOGICAL STUDIES OF THE COMPOUNDS ACCORDING TO THE INVENTION

1. Endotoxicity determination by the *Limulus* Chromogenic test

Endotoxicity was determined by a chromogenic *Limulus Amoebocyte Lysate* test (Chromogenic LAL of Charles River Endosafe, batch # EK412 E, Charleston, USA). This test is based on activation by a lipopolysaccharide (LPS) or structurally analogous products, of an enzymatic cascade present in LAL. This enzymatic activation is demonstrated by cleavage of a chromogen linked to a peptide under the action of a protease, at the final stage of this enzymatic cascade according to the following reaction scheme :

LPS or PRODUCT



5

LAL protease activation and hydrolysis of a peptide/chromogen molecule



10 Ac-Ile-Glu-Ala-Arg-p-nitroaniline -----> Ac-Ile-Glu-Ala-Arg + p-nitroaniline
(colorless) colored (405 nm)

15 The enzymatic reaction is conducted at 37°C and the time-course chromogen formation is measured at 405 nm. In the final stage of this time-course determination assay, the time required to achieve an OD of 0.2 unit is recorded and the endotoxic activity is calculated based on an LPS standard (standard curve).

20 Results are expressed in EU (Endotoxin Unit) in relation to a standardized preparation of *E. coli* lipopolysaccharides. For this series of assays, 1 EU corresponds to 0.08 mg of LPS equivalent.

25 The results show a relatively high degree of variability, though this is normal for such a kind of quantitative assays which provides, in essence, an indication on magnitude. LAL testing is chiefly conducted to demonstrate the absence of pyrogens (upper limit of endotoxin concentration) in pharmaceutical preparations. It is mandatory to compare the quantitative assay of the pyrogen content with a given well standardized single series of experiments.

30 **Results**

The results (mean \pm standard deviation) obtained for the products of the invention are set forth in Table (A) :

Table (a) Activation of limulus amoebocyte lysate (LAL)

Products	LAL activity in EU/mg	LAL activity in LPS equivalents ng eq. LPS/mg
OM-294-DP	56 \pm 48	6.2
OM-294-MP	13 \pm 2	1.4
<i>E. coli</i> LPS (reference)	7.7 \pm 1.6 X 10 ⁶	0.85 x 10 ⁶

5 The compounds of the invention are 10⁶-fold less active than LPS in the LAL test. OM-294-DP and OM-294-MP are therefore particularly interesting products by virtue of their low toxicity, when taken together with their ability to mediate biological activities and act as immunomodulators (both *in vivo* and *in vitro*).

10 **2. Determination of bone marrow stem cell proliferation of mice in response to LPS stimulation or compounds according to the invention**

Procedure

Two six-week old male C57/BL6 mice were killed by CO₂ inhalation followed by cervical dislocation. The mice were washed with alcohol, and the skin of the posterior members was entirely removed. The hip, femur and tibia bones were removed by joint disruption. The flesh was grossly removed using a scalpel. The bones were cleaned and the bone ends were cut with scissors. The marrow was extracted from the bone lumen by injecting three times 1 ml of Dulbecco's Modified Eagle Medium (DH medium) from the the extremities which were cut with scissors. The cells were suspended in DH medium and centrifuged at 300 x g for 5 minutes. The supernatant fluid was discarded and the stem cells were suspended in DH medium supplemented with 20% foetal calf serum (FCS) The cell concentration was adjusted to 500 000 cells/ml.

25 Products previously dissolved in DH medium supplemented with FCS, amino acids and antibiotics were serially diluted, directly into 96-well

microtiter plates. 9 dilutions are performed using a dilution factor of 3.16. The products are tested in series of six and each microtiter plate includes a negative control containing plain medium. The final volume in each well is 100 μ l. The microplates are incubated for 1 hour at 37°C under 8% CO₂ - 100% RH incubator to buffer the medium. After 1 hour, 100 μ l of the cell suspension are added to the products and incubation is continued for 7 days.

Proliferation is determined by measuring the oxydation of a chromogenic substrate (XTT) in mitochondria of viable cells.

7 days later, the microtiter plates are centrifuged for 5 minutes at 400 x g, and 100 μ l of the supernatant fluid are withdrawn and discarded. 50 μ l of a 1 mg/ml XTT sodium 3-[1-phenylamino-carbonyl)-3, 4-tetrazolium]-bis[(4-methoxy-6-nitro)benzene sulfonate] and 0.008 mg/ml PMS ((N-methyl dibenzopyrazine, methyl sulfate) in RPMI medium are added to each well. After 8 hour incubation at 37°C under 8% CO₂ in an incubator at 100% RH, the microtiter plates are read with a spectrophotometer at 480 nm against a standard at 690 nm.

The results are expressed as mean values (\pm standard deviation) by plotting a dose versus response curve. The values of the negative control composed of DH medium (mean \pm standard deviation of all experimental data) are also graphically shown.

In this experiment, compounds according to the invention induce a significant cell proliferation of mouse bone marrow stem cells. The extent of such a response is nearly equal to that induced by *E. coli* LPS, but the minimal concentration required to induce a significant response is higher. The monophosphorylated product induces a more moderate response than the diphosphorylated product. Figure 1 depicts a representative experiment derived from a set of three independant studies run on different cellular preparations.

3. Determining the production of nitric oxide in the supernatant fluids of macrophage cultures.

Procedure

Two six-week old male C57/BL6 mice were killed by CO₂ inhalation followed by cervical dislocation. The mice were washed with alcohol, and the skin of the posterior members was entirely removed. The hip, the femur

- and the tibia bones were removed by joint disruption. The flesh was grossly removed using a scalpel. The bones were cleaned and the bone ends were cut with scissors. The marrow was aspirated by injecting three times 1 ml of Dulbecco's Modified Eagle Medium (DH medium) in the bone lumen.
- 5 The cells were resuspended in DH medium and centrifuged at 300 x g for 5 minutes. The supernatant fluid was discarded and the cells were resuspended at a density of 40 000 cells/ml in DH medium supplemented with 20% horse serum (HS) and 30% L929 culture supernatant. L929 is a murine fibroblast cell line the supernatant fluid of which is rich in growth
- 10 factor for macrophage (M-CSF). The cell suspension was divided into 12 ml aliquots in Petri dishes which were incubated for 8 days in an incubator at 37°C under 8% CO₂ and 100% RH. After 8 days, the stem cells differentiated into mature macrophage cells. The macrophage cells were scraped off by incubating them for 45 minutes at 4°C in cold PBS buffer.
- 15 After centrifugation and removal of the supernatant fluid, the cells were resuspended in DH medium supplemented with 5% foetal calf serum (FCS), glutamine, asparagine, arginine, folic acid, mercaptoethanol, and antibiotics (penicillin and streptomycin). The stem cells were collected and cellular density was adjusted to 700 000 cells/ml.
- 20 Products previously dissolved in DH medium supplemented with FCS, amino acids and antibiotics were serially diluted directly in 96-well microtiter plates. 9 to 10 dilutions depending on the products were conducted using a 3.16 dilution factor. The products were tested in triplicate and each microtiter plate comprised a negative control containing
- 25 plain medium. The final volume in each well was 100 µl. The microtiter plates were incubated for 1 hour in an incubator at 37°C under 8% CO₂ and 100% RH to buffer the medium. After 1 hour, 100 µl of the cell suspension were added to the products and incubation was extended for 22 hours.
- 30 After 22 hours, the microtiter plates were centrifuged, 5 minutes at 400 x g and 100 µl of supernatant fluid were withdrawn and transferred into a microtiter plate. 100 µl of Griess reagent [5 mg/ml of sulfanilamide + 0.5 mg/ml of N-(1-naphthylethylene diamine) hydrochloride in 2.5% aq. phosphoric acid], were added to each well. The microtiter plates were read
- 35 with a spectrophotometer at 562 nm wavelength against a reference at 690

nm. The nitrite concentration was proportional to nitric oxide content. The nitrite content is determined based on a standard curve, which shows a linear relationship in the range of 1 to 25 μ M.

The results are expressed as mean \pm standard deviation after
5 deduction of the negative control value and plotted as a dose versus
response curve.

In this experiment, the compounds according to the invention
induce the production of nitric oxide by murine macrophage cells in a
manner consistent with a dose vs. response curve. The diphosphorylated
10 product induces proliferation to a much greater extent than *E. coli* LPS, but
the concentration required to induce a significant response is higher. The
monophosphorylated product induces a weaker response compared to that
obtained using the diphosphorylated product and that of *E. coli* LPS. Figure
2 depicts a representative experiment derived from a set of 3 independant
15 measurements run on different cell preparations.

4. Determination of the ability of compounds according to the invention to elicit the production of α -TNF by human alveolar macrophage cells

Procedure

5 Preparation of alveolar macrophage cells: Human alveolar macrophage cells were obtained by bronchoalveolar washing (BAL) of lungs in patients suffering from lung cancer. BAL is conducted immediately after pulmonary tissue surgery involving healthy parts of the pulmonary lobe. Washings are performed using 0.8% NaCl with the aid of a 50 ml capacity syringe. Cells recovered are made up for greater than 85% of macrophage cells, the majority of other cells being lymphocytes. After centrifugation, the cells are suspended into RPMI medium and the red blood cells are removed by centrifugation on (Research-Grade) Ficoll Pack. The macrophage cells are washed 3 times with HBSS and seeded into 24-well microtiter plates at a rate of 1 ml per well containing a total of 1 000 000 cells. After incubation for 1 hour at 37°C, the resulting macrophage cells become adherent and the wells are washed three times with 1 ml of HBSS in order to remove non adherent cells. After the washing step, 1 ml of RPMI is added to each macrophage cell-containing well.

20 Incubation with products and assay of α -TNF: Alveolar macrophage cells are incubated at 37°C under 5% CO₂ in the presence of 0.1 µg/ml, 1µg/ml and 10 µg/ml concentrations of the following products :

- Negative control : RPMI
- Positive control : *E. coli* LPS (serotype O5 : B5 , Difco, Detroit, U.S.A.)
- 25 - Monophosphorylated compound according to the invention (OM-294-MP)
- Diphosphorylated compound according to the invention (OM-294-DP)

The culture supernatants are recovered after 24 hours and analyzed for α TNF content (BioSource Cytoscreen Kit, Camarillo, CA, U.S.A) which has a sensitivity of 1 pg/ml.

Results

30 The monophosphorylated and diphosphorylated derivatives pursuant to the invention induce moderate production of α TNF in concentration as low as from 10 µg/ml. The monophosphorylated derivative according to the invention induces α TNF production to a higher extent than the

diphosphorylated one. The LPS positive control induces at all three tested concentrations high production of α TNF.

The results are listed in Table (a)

5 **TABLE (a) Induction of α TNF production by OM-294-MP and OM-294-DP in human alveolar macrophage cells**

Product	α TNF [pg/ml] mean \pm standard deviation of 3 independent experiments			
	0 μ g/ml	0.1 μ g/ml	1 μ g/ml	10 μ g/ml
Negative control : RPMI	195 \pm 70			
Positive control : <i>E. coli</i> LPS		7667 \pm 115	9858 \pm 2148	10390 \pm 3415
OM-294-MP-1		246 \pm 38	353 \pm 75	1049 \pm 295
OM-294-MP-2		205 \pm 62	291 \pm 70	1124 \pm 406
OM-294-DP-1		156 \pm 66	117 \pm 85	329 \pm 141
OM-294-DP-2		171 \pm 79	88 \pm 61	

10 **5. Determining the capacity of compounds in accordance with the invention to inhibit α TNF production in human alveolar macrophage cells, in response to *E. coli* Lipopolysaccharide (LPS)**

Procedure

15 Preparation of alveolar macrophage cells: Human alveolar macrophage cells were obtained by bronchoalveolar washing (BAL) of lungs in patients suffering from lung cancer. BAL is conducted immediately after pulmonary tissue surgery involving healthy portions of the pulmonary lobe. Washings are performed using 0.8% NaCl with the aid of a 50 ml capacity syringe. Cells recovered are made up for greater than 85% of macrophage cells, the majority of other cells being lymphocytes. After
20 centrifugation, the cells are suspended into RPMI medium and the red blood cells are removed by centrifugation on (Research-Grade) Ficoll Pack. The macrophage cells are washed 3 times with HBSS and seeded into 24-well microtiter plates at a concentration of 1 ml per well containing a total of 1 000 000 cells. After incubation for 1 hour at 37°C, the resulting

macrophage cells become adherent and the wells are washed three times with 1 ml of HBSS in order to remove non adherent cells. After the washing step, 1 ml of RPMI is added to each macrophage-containing well.

Incubation with products and α TNF assay : Alveolar macrophage cells are incubated at 37°C under 5% CO₂ in the presence of *E. coli* LPS (O5 : B5 serotype, Difco, Detroit, U.S.A.) at 1 mg/ml to which are added simultaneously the following products at a concentration of 10 µg/ml :

- Negative control : RPMI
- Monophosphorylated compound according to the invention (OM-294-MP)
- Diphosphorylated compound according to the invention (OM-294-DP)

The culture supernatant fluids are recovered after 24 hours and analyzed for α TNF content (BioSource Cytoscreen Kit, Camarillo, CA, U.S.A) which has a sensitivity of 1 pg/ml.

Results

The diphosphorylated derivative considerably inhibits the production of α TNF normally induced by LPS. The monophosphorylated derivative partially inhibits α TNF producton induced by LPS.

The results are set forth in Table (a)

TABLE (a) Inhibition of LPS-induced α -TNF production by OM-294-MP and OM-294-DP in human alveolar macrophage cells

Product	α TNF [pg/ml]	% inhibition
RPMI (negative control)	73	-
<i>E. coli</i> LPS (10 µg/ml) (positive control)	8470	0
OM-294-MP-1 (10 µg/ml) + <i>E. coli</i> LPS (1 µg/ml)	4577	44
OM-294-MP-2 (10 µg/ml) + <i>E. coli</i> LPS (1 µg/ml)	4789	41
OM-294-DP-1 (10 µg/ml) + <i>E. coli</i> LPS (1 µg/ml)	1267	84
OM-294-DP-2 (10 µg/ml) + <i>E. coli</i> LPS (1 µg/ml)	1280	84

6. Effect of OM-294-MP and OM-294-DP products on dendritic cell maturation

The ability of OM-294-MP and OM-294-DP products to induce maturation of predendritic cells into dendritic cells was evaluated. The following parameters were measured: FITC-Dextran conjugate incorporation and expression of CD40, CD80, CD83, CD86 surface markers.

Procedure

Cells : Mononucleated cells of peripheral blood are isolated from buffy coats of six healthy donors. Donors did not undergo any treatment prior to blood donation.

Cell preparation : Purified monocytes by adherence selection are resuspended in RPMI-1640 medium (Sigma-Aldrich : St.-Louis, MO, U.S.A) containing 10% of foetal calf serum, GM-CSF (10 ng/ml; IM-HGMI, Immungenex Corp., Los Angeles, CA, U.S.A.) and IL-4 (10 ng/ml; No 204-IL, R&D System, Minneapolis, MN, USA) at a density of 1×10^6 cells/ml and divided into Petri Dishes of 10 cm in diameter (P10, Falcon, Becton Dickinson, Plymouth, UK) (10×10^6 cells per dish P10) and cultured for 6 days (with a change to fresh medium after 3 days). These cells are called predendritic cells (DC-6). Maturation of predendritic cells into mature dendritic cells is achieved by incubating cells with OM-294-MP, OM-294-DP or LPS for 3 further days at concentrations set below under Product section. At day 9, (DC-9) cells were harvested and analyzed for different indicators of dendritic cell maturation : assessment of CD40, CD80, CD83, CD86 surface markers as well as of their ability to take up FITC-Dextran conjugate. All theses parameters are analyzed by an EPICS-XL-MCL model FACS (Coulter Immunology, Hialeah, Finland).

Lanzavecchia et al., J. Exp. Med., 179 (1994) 1109; Lanzavecchia et al., J. Exp. Med., 182 (1995) 389.

Data analysis : Expression of surface markers is expressed as % of mean fluorescence of cells stimulated by LPS (positive control); FITC-Dextran conjugate take-up is calculated with respect to take-up rate for cells maintained in basic medium and is expressed in %. Statistic analysis by t-student test involves comparing data obtained from different tests with the data of a positive control. Data significance level is set at $p < 0.05$.

Products : Stock solutions of OM-294-MP and OM-294-DP are prepared at a concentration of 1 mg/ml in 0.9% NaCl/water, with 0.1% triethylamine being added in case of OM-294-MP. Solutions are incubated at 37°C for 20 minutes, subjected to vigorous stirring during 3 minutes then
 5 diluted to 100 µg/ml in RPMI-1640 culture medium and used either at a concentration of 10 mg/ml (Figures 3, 6, 7, 8) or at concentrations ranging from 0.02 to 25 µg/ml (Figures 4, 5).

Reference Product : *E. coli* lipopolysaccharide (LPS, DIFCO, Detroit, MI, USA), as a 5 mg/ml stock solution in PBS. An intermediate 100
 10 µg/ml solution is prepared in RPMI 1640 culture medium. Concentrations being tested are either 10 µg/ml (Figures 3, 6, 7, 8) or in the range of 0.02 to 10 µg/ml (Figures 4, 5).

Results

Immature dendritic cells (DC-6) resulting from monocyte
 15 differentiation, through the joint action of GM-CSF and IL-4, are able to incorporate FITC-Dextran conjugate. During the maturation process, cells lose their ability to incorporate the FITC-Dextran conjugate. Analysis are conducted upon reaching the DC-9 differentiation stage.

Results are expressed in terms of % incorporation of FITC-Dextran conjugate observed in non stimulated cells (basic medium) Figure (3). Cells treated with LPS or OM-294-MP retain respectively only 10% and 19% of their phagocytic capacity, whereas cells stimulated with OM-294-DP totally retain their ability to incorporate FITC-Dextran conjugate (98 and 99%). A dose vs. response curve indicates that OM-294-MP has an outstanding
 20 capacity to induce differentiation of DC-6 into DC-9 cells at concentrations ranging from 0.02 µg to 25 µg per ml, see Figure (4) where low concentrations and Figure (5) where higher concentrations have been tested.

Expression of co-stimulating surface markers is another criterion to
 30 assess DC maturation. Expression of CD40, CD80, CD83, CD86 is tested. Results are expressed in terms of % of mean fluorescence based on LPS-induced expression of these markers.

OM-294-MP increases the expression of all surface markers being tested : CD40(39%), CD80 (62%), CD83 (60%), CD86 (77%) see Figures
 35 (6, 7, 8, 9).

OM-294-DP exerts an effect similar to that of basic culture medium upon expression of the investigated markers. Such an effect does not exceed 20% of LPS action.

5 **7. Effect of OM-294-MP and OM-294-DP products on production of α TNF and IL-12 p70 by monocytes and predendritic cells at DC-6 stage**

DC-6 cells (5×10^5 /500 μ l of medium) are stimulated during 4 hr., 6 hr., and 24 hr., either by LPS (10 μ g/ml) or by OM-294-MP (10 μ g/ml) or OM-294-DP (10 μ g/ml).

10 **Procedure**

In vivo experimental conditions : Mononuclear cells of peripheral blood are recovered from buffy coats of 6 healthy donors (donors did not undergo any treatment prior to blood donation). Monocytes are isolated in a Ficoll gradient then purified by adherence selection. Loosely adherent
15 monocytes are harvested and one fraction of the cells is stored as monocytes. Purified monocytes are resuspended into RPMI -1640 medium containing 10% of FCS, at a rate of 1×10^6 cells/ml and divided into Petri dishes measuring 10 cm in diameter (P10 - Falcon, Becton Dickinson, Plymouth, UK) at a rate of 10×10^6 cells/P10 type dish. Cells are cultured
20 in whole RPMI 1640 medium containing GM-CSF (10 ng/ml) and IL-4 (10 ng/ml) during 6 days. At day 6, cells are harvested, washed with HBSS and seeded into a 24-well plate at a density of 5×10^5 cells/well in 500 μ l of whole RPMI medium and stimulated with LPS (10 μ g/ml), OM-294-MP (10 μ g/ml) or OM-294-DP (10 μ g/ml). α TNF as well as IL-12 p70 are assayed
25 by ELISA in culture supernatants which are recovered after 4, 6 and 24 hours.

Products : OM-294-MP and OM-294-DP products (1 mg/ml stock solution in sterile water) are incubated at 37°C during 20 min. and kept under vigorous stirring during 3 minutes then diluted to 100 mg/ml and
30 used at a final concentration of 10 μ g/ml in RPMI 1640 culture medium.

Reference Product : *E. coli* lipopolysaccharides (LPS, DIFCO, Detroit, MI, USA), 5 mg/ml stock solution in PBS, intermediate solution in culture medium : 100 μ g/ml, used at a final concentration of 10 μ g/ml.

Assay of α TNF and IL-12 p70 : α TNF KHC3012 kit from
35 Biosource, batch # PP003-J061703 (Biosource International, Camarillo,

CA, USA) ELISA was run according to the supplier's instruction manual. IL-12 p70 is assayed in culture supernatants by ELISA using the human IL-12 kit (No. D1200, batch 990 6232, R&D Systems, Minneapolis, MN, USA).

Results

α TNF

OM-294-MP stimulates α TNF production by DC-6 cells in a way similar to LPS both with respect to time-course production rate and α TNF concentration. (Figure 10)). An α TNF peak is noted for both products between 6 hr. and 24 hr..

OM-294-DP has only a minor stimulating effect on α TNF production by DC-6 cells.

IL-12 p70

Generally speaking, IL-12 is induced in presence of γ IFN (LPS + γ INF, OM-294-MP + γ IFN) in monocytes ((Figure (12)) and DC-6 cells ((Figure 11)). Cytokine production onset is earlier in DC than in monocytes.

8. Evaluation of OM-294-MP and OM-294-DP adjuvant properties in a murine immunization model with a synthetic peptide (Pb CS His₆- 242 - 310) of the C-terminal region of *Plasmodium berghei* circumsporozoite surface proteine

Procedure

Antigen : Pb CS (HHHHHHGGMN NKNNNNDDSY
IPSAEKILEFVKQIRDSITE EWSQCNVTCG SGIRVRKRKRKG
SNKKAEDLTL EDIDTEI) peptide, hereinafter referred to as His₆-242-310, corresponding to 242-310 amino acid sequence of *Plasmodium berghei* circumsporozoite ANKA strain surface proteine plus an N-terminal stretch of 6 histidine, 2 glycine and one methionine residues is obtained by the Merrifield and Atherton synthesis method (Athenon et al., Bioorg Chem., 8 : (1979) 350 - 351). The polypeptide was prepared on a p-alkoxybenzylalcohol resin (Wang resin) having a substitution rate of 0.4 mmol/g. A 10-fold molar excess of F-moc amino acid derivatives is used with a coupling time of 30 min. The peptide is purified by size exclusion chromatography (Sephadex G25, Pharmacia, Sweden) then by reverse phase chromatography (W-Porex 5 C-4, 250 x 10 mm, Phenomenex, Torrance, CA, U.S.A) using a 40-min. gradient, ranging from a 10-50% acetonitrile-0.1% trifluoroacetic acid mixture (v/v), at a 3 ml/min. flow rate.

The amino acid composition of the peptide is determined according to the method of Knecht and Chang (*Anal. Chem.*, **58** (1986) 2373-2379) and the molecular weight is checked by mass spectrometry using a Voyager DE model apparatus (Perspective Biosystem, Framingham, MA, USA). Antigen stock solution is prepared at a concentration of 0.4 mg/ml in 0.9% NaCl/water at pH 8.0.

Adjuvants : Stock solutions of OM-294-DP and OM-294-MP are prepared at a concentration of 1 mg/ml in 0.9% NaCl-water, incorporating 0.1% triethylamine for OM-294-MP. The positive control is comprised of Incomplete Freund's Adjuvant (IFA from Difco, Detroit, MI, USA) with the negative control being a 0.9% NaCl solution.

Antigen-adjuvant mixture : One volume of antigen and one volume of adjuvant are mixed by vortexing for 3 min.

Immunization regimen : 6-week old female BALB/c mice (6 mice per group) are immunized three times, with a subcutaneous shot in the tail end containing 0.1 ml of the following mixtures :

Group	adjuvant 0.05 mg/injection	antigen 0.02 mg/injection	number of mice
1	-	Pb CS His ₆ -242-310	6
2	IFA	Pb CS His ₆ -242-310	6
3	OM-294-MP	Pb CS His ₆ -242-310	6
4	OM-294-DP	Pb CS His ₆ -242-310	6
5	OM-294-MP	-	6
6	OM-294-DP	-	6

Immunization and sampling schedual :

Weeks	0	3	4	7	9
Immunizations	↑	↑		↑	
Antibody specific response	↑	↑		↑	↑
CTL response			↑		↑

Lymphoid organ and blood sampling :

Serum sampling : Blood sampling is conducted at weeks 0, 3, 7 and 9. Blood is allowed to stand for 6 min. at 37°C, then is kept overnight at 4°C. Serum is subsequently frozen at -80°C until time of antibody assay.

5 Recovery of inguinal lymph nodes and spleen : A portion of each animal group is killed after 4 or 9 weeks, respectively. Inguinal lymph nodes and the spleen are surgically removed.

Determination of anti-Pb CS His₆ 242-310 antibody titer :

Assay of antibodies specifically raised against Pb Cs His₆ 242-310 antigen is performed by ELISA. Binding of antigen is done in 96-well microtiter plates (Maxisorp F96, Nunc, DK) by conducting overnight incubation in a moist chamber at 4°C with each well containing 0.1 ml of PBS (phosphate buffered saline) containing 0.001 mg/ml of Pb CS His₆ 242 - 310 antigen. Blocking of the microtiter plate is performed with PBS containing 1% of bovine serum albumin (BSA, Fluka, Switzerland). Plates are washed with PBS containing 0.05% Tween 20 (Sigma, St. Louis, MO, USA). Serum samples collected at 0, 3, 7 and 9 weeks are serially diluted with dilution buffer (PBS containing 2.5% of skimmed milk powder and 0.05% of Tween 20), then transferred into a microtiter plate and allowed to stand for 1 hr. at room temperature (RT). Plates are then washed with PBS, a diluted solution containing mouse polyclonal anti-immunoglobulin coupled to alkaline phosphatase (Sigma, St. Louis, MO, USA) is then dispensed into those plates and incubated for 1 hr. at RT. Plates are washed with PBS and specific antibodies are revealed by a color reaction by adding the alkaline phosphatase substrate, p-nitrophenylphosphate (Sigma, St. Louis, MO, USA). Absorbance at 405 nm is read with a microtiter plate reader (Dynatech 25000 ELISA reader, Ashford, Middlesex, UK), each serum sample is measured in duplicate. Results stand for the mean of all measurements relating to mice in each group. The antibody titer is given by the highest dilution giving a significantly positive response, i.e. an OD greater to background noise level ± 3 SD.

ELISPOT assay :

Antibodies specifically directed to murine γ -interferon (O1E703B2) are bound by running an overnight incubation at 4°C in a moist chamber, adding an antibody solution at 50 μ g/ml in an ELISPOT microtiter plate with

the well bottom being covered by nitrocellulose (Millipore, Molsheim, France). The blocking step is effected by adding DMEM medium (Life Technologies, Grand Island, NY, USA) containing 10% of foetal calf serum (FCS, Fakola, Switzerland) and letting stand for 2 hours at 37°C. Cells obtained from lymphoid organs (inguinal lymph nodes and spleen) are cultured in microtiter plates at a density of 200 000 cells/well, then co-cultured during 24 hours at 37°C with 100 000 P815 cells either challenged or not with the Pb CS 245-252 short peptide. After incubation, cells are removed and following the washing step, a second murine anti- γ IFN antibody-biotin complex (ANI, 2 μ g/ml in PBS with 1% BSA) is added and incubated for 2 hr. A streptavidin-alkaline phosphatase conjugate (Boehringer Mannheim, Mannheim, GFR) is added and incubated for 1 hr at 37°C, and thereafter 3 washings are effected with PBS containing 0.05% Tween 20, followed by 3 washings with PBS. Presence of anti- γ IFN immune complexes is demonstrated by adding BCIP/NBT substrate (Sigma, St. Louis, MO, USA). This reaction is stopped by washing with tap water. Spots which are positive for γ IFN are then counted under a stereomicroscope. Specific spot count is the difference between spots counted in presence of cells challenged with peptide and spots counted in absence of peptide. Results are given as mean measurement values recorded for mice in each group. They are expressed as the number of spots per million of cultured blood cells.

Results

Antibody response : Production of antibodies specifically directed to Pb CS His₆-242-310, as determined by ELISA, is graphically depicted for mice administered one, two and three immunization shots. The control involves one single shot of antigen alone and results in a very weak antibody titer. Antibody titer achieved with one single antigen shot in admixture with OM-294-MP or respectively OM-294-DP is almost as high as the response observed with Incomplete Freund's Adjuvant (IFA) in admixture with the same antigen (Figure (13)). After two shots, OM-294-MP and OM-294-DP adjuvants are able to elicit a serological response which is respectively greater than that of IFA (Figure (14)). Following three shots, OM-294-MP and OM-294-DP adjuvants are able to elicit a serological response which is greater than that of IFA (Figure (15)).

Figure (13) ELISA, run 3 weeks after the first immunization shot.

Figure (14) ELISA, run 4 weeks after the second immunization shot.

Figure (15) ELISA, run 2 weeks after the third immunization shot.

Figure (16) Antibody titer as measured before and after one, two
5 and three immunization shots.

Antibody titers of animals in each group before an immunization shot and after one, two and three immunization shots are given as mean values (Figure (16)).

CTL Response : Recognition of the T-cell epitope Pb CS 245-252
10 present in Pb CS His₆-242-310 peptide previously used for immunization is well demonstrated by the ELISPOT test. T-lymphocyte response recorded in immunized animals (inguinal lymph nodes and spleen, recovered one week after the second shot and respectively two weeks after the third shot) is demonstrated by the rise in positive spot count for γ interferon (γ IFN).
15 Results set forth in the Figures (17, 18, 19 and 20) are calculated as mean value of measurements achieved with each dilution and for mice of each group. They are expressed in number of spots per million cells in culture.

Both OM-294-MP and OM-294-DP adjuvants result in a very
20 significant increase in CTL response of lymphocytes derived from spleen and inguinal lymph nodes. Spleen responses are higher than those of inguinal lymph node responses. CTL activity induced by OM-294-MP and OM-294-DP adjuvants is clearly superior to the one induced by IFA.

9. Demonstrating non covalent OM-294-antigen complexes by capillary electrophoresis

25 Capillary electrophoresis is used in this example to demonstrate non covalent complex formation between OM-294-DP and Pb CS His₆-242-310 peptide during formulation of the vaccine preparation.

Procedure

Analysis method : 20 mM sodium borate buffer (di-sodium
30 tetraborate decahydrate, Merck, N° 6306) pH adjusted to 7.4 with 1N NaOH (Fluka N° 72072)

Zone-divided capillary tube (ungrafted), length 30 cm, diameter 50 μ m.

35 Detection is performed at 200 nm using a Beckman PACE MDQ model apparatus (Beckman, Brea, CA, USA).

Separation conditions

Time [min.]	process	Pressure	Solvent
0.00	Capillary wash	20.0 psi	H ₂ O
3.00	Capillary wash	20.0 psi	1N NaOH
6.00	Sample injection	0.5 psi	Borate buffer
6.08	Separation	30.0 KV	Borate buffer

Antigens : Pb CS His₆-242-310 synthetic peptide at 1 mg/ml in H₂O

Adjuvant : OM-294-DP at 1 mg/ml in H₂O

Antigen-adjuvant mixture : 250 µg/ml + 250 µg/ml

Results

Antigen-adjuvant complex formation as observed in formulating this vaccine preparation is demonstrated on the electrophoresis diagram by the disappearance of the adjuvant peak and a shift in the antigen peak giving rise to a new peak which is specific of the newly formed complex (Figure (21)).

10. Treatment of peritoneal carcinoma induced by injection of cells derived from PROb syngenic tumoral line in BDIX rats

This experiment is aimed at demonstrating an antitumoral effect of OM-294-DP when administered in a series of i.v. shots to rats bearing macroscopic tumors of a few mm in size.

Procedure

Animals : In-bred BDIX rat strain was established by H. Druckrey in 1937. A pair of rats from Fribourg Max Planck Institute (RFA) was the initial source of this colony which has been maintained since 1971 in the laboratory animal house facility by the single line system. According to this system, one single pair of sister-brother subjects is selected to give rise to the descendants of the next generation. Rats used in this work are from the Experimental Animal Breeding Center in Iffa-Credo (Arbresle, France) which has been conducting the breeding on behalf of the applicant's laboratory. Rats used are males aged 3 months \pm 1 week.

Tumor induction by PROb cell injection :

PROb Cell origin : DHD/K12 cell line was initially derived from a graft of a colon carcinoma fragment induced in an in-bred BDIX rat by 1, 2-

dimethylhydrazine treatment. This line of adherent cells was subdivided into two sublines depending on their sensitivity to trypsin treatment, and cells which are hard to break-off were given the name of DHD/K12-TR. DHD/K12-TR cells when injected in syngenic BDIX rats give rise to steady-developing tumors. This line has been cloned, only DHD/K12-TRb clone referred to as PROb was used in the present investigation.

Culture conditions : Adherent PROb cells were cultured in sealed bottles (Falcon, Becton Dickinson, New Jersey, USA) at 37°C in complete medium made up of Ham's F10 medium (Bio-Whittaker, Walkersville, USA) to which 10% foetal calf serum (FCS, Anval, Betton, France) were added. Replacement of culture medium was done every 3 days. Upon reaching confluency, cells were released or scraped off within 3 to 5 min from the support by 2 ml of EDTA/trypsin solution, following 3 rinses with 2ml of the same solution for 2 - 3 minutes; cells were resuspended into whole medium, with addition of FCS to stop trypsin action. The absence of contamination in cells of mycoplasma and bacterial origin was checked at regular intervals by DNA dyeing with Hoechst fluorochrome 33258 (Aldrich Chimie, Steinheim, GFR).

Induction of peritoneal carcinoma : PROb cells are released from their support as set forth in "culture conditions" section and are counted in a trypan blue coloring agent solution as a means for assessing cell viability. Cells are suspended in Ham's F10 medium. Peritoneal carcinomas are induced by intraperitoneal injection (i.p.) of 10^6 viable PROb cells into a syngenic BDIX rat under ether anesthesia. Tumor cell injection is done on Day 10. In these conditions, all rats develop a peritoneal carcinoma with production of bloody ascites and die between the 6th day and the 12th day following cell injection.

Treatment of peritoneal carcinoma : Treatment is initiated 13 days after injection of tumoral cells when carcinoma masses are made up of nodules of a few mm in diameter. Treatment is administered by 10 i.v. injections of OM-294-DP at a rate of 1 mg/kg of body weight and in doses of 0.6 mg/ml dissolved in 0.9% NaCl solution. Injections are administered 3 times a week (monday, wednesday and friday) in the penile vein. Control group is treated with vehicle alone i.e. 0.9% NaCl.

Assessing treatment efficiency : At D42, 6 weeks after injecting tumor cells, rats are killed and dissected, carcinoma development is assessed through a blind study. Measuring carcinoma volume is not feasible, instead, it is possible to classify carcinomas into 4 different types.

5 Five classes are defined according to the number and diameter of nodules.

Class 0 : No nodules are visible

Class 1 : Nodules of 0.1 to 0.2 cm in diameter are readily counted

Class 2 : Countless nodules of 0.1 to 0.5 are seen

10 Class 3 : Peritoneal cavity is invaded by nodules, some of which measure 1 cm in diameter.

Class 4 : Cavity is completely invaded with tumor masses of a few cm in size.

15 Ascite volume and animal weight change : Ascite volume is measured by weighing animals twice. A group of control rats, to which no treatment but only 0.9% NaCl injections had been administered, allows normal development of carcinomas to be assessed and treatment follow-up.

20 Assessing treatment efficiency : Survival rate of rats in treated groups is compared to survival rate in control groups; carcinoma and ascite volumes of rats in treated groups are compared to measurements derived from rats in the control group.

25 Statistical analysis : Statistical significance of immunotherapy effect is determined using Kruskal-Wallis test for classifying carcinomas. Likewise, a variance analysis test is conducted for ascite volume data, and a log rank test is performed for survival rates.

Results

30 Carcinomas : OM-294-DP shows a remarkable anti-tumor activity in this model. This activity is more specifically demonstrated by the number of tumor-free animals (class 0) and further the difference with NaCl control is significant ($p < 0.05$) for tumor volume. Impact of treatment with OM-294-DP on ascite volume is also significant ($p < 0.05$).

Table (a) Carcinoma classification and ascite volume

Treatment	Number of rats suffering from carcinoma belonging to class					Effect of product (*)	Volume ascite in ml/rat		Effect of product (**)
	0	1	2	3	4		range	mean $\pm\sigma$	
NaCl ⁽¹⁾	1	0	1	0	7	-	0-84	38 \pm 29	-
OM-294-DP ⁽²⁾	4	1	2	1	2	p < 0.05	0-73	8 \pm 23	p < 0.05

(*) : Kruskal-Wallis test, (**) : Variance analysis.

⁽¹⁾ : 8 to 10 rats died from cancer before being killed, 1 rat at D34 displayed nodules and jaundice but no accurate class determination could be made (cannibalism), 1 rat at D37 belonged to (class 4), 2 at D38 belonged to (class 4); 1 at D39 belonged to (class 4), 2 at D40 belonged to (class 4) and 1 at D41 belonged to (class 4). One rat of class 0 displayed upon dissection a subcutaneous tumor, it is likely that injection of cancer cells failed.

⁽²⁾ : 1 rat died at D14 at the time of the first treatment injection, the latter did not suffer from carcinoma. One of the rats killed in class 0 showed a subcutaneous tumor (injection of cancer cells failed).

Survival :

Animals are killed at D42. Survival was determined at day 42 following injection of tumor cells, 90% of animals treated with OM-294-DP survived, whereas for the untreated group only 20% of animals were still alive.

Rat survival rate is significantly extended by OM-284-DP ($p < 0.001$).

Weight : OM-294-DP has no significant effect on weight change in comparison to animals administered NaCl alone as demonstrated by data in Table (b).

Table (b) Weight change in rats (mean \pm standard deviation)

Days	NaCl	OM-294-DP
0	314 \pm 19	277 \pm 19
13	337 \pm 18	310 \pm 21
20	342 \pm 20	304 \pm 23
29	361 \pm 23	317 \pm 24
41	314 \pm 38	327 \pm 26

11. Evaluation of OM-294-DP adjuvant properties in a murine immunization model through nasal administration of urease B subunit of *Helicobacter pylori*

It has been shown that mice can be protected from *Helicobacter pylori* infection when immunized with urease B subunit of *Helicobacter pylori* either by oral or nasal administration in presence of a *cholera toxin* (CT) based adjuvant. Corthésy-Teulaz I., et al., Gastroenterology, **109** : (1995) : 115; Michetti P. et al., Gastroenterology, **116** : (1999) 804; Saldinger P.F. et al., Gastroenterology **115** : (1998) 891. This anti-Ure B humoral response as measured in serum of immunized mice is mainly of the IgG1 type (Th2 response). Adjuvant effect evaluation of OM-294-DP is conducted in BALB/c mice (n=6) immunized four times at intervals of one week by nasal administration of urease B subunit (UreB) of recombinant *Helicobacter pylori* in presence of OM-294-DP. BALB/c control mice were immunized with OM-294-DP adjuvant alone. Two weeks following the last

booster, blood is sampled from each mouse to assay serum anti-UreB immunoglobulins by ELISA (total IgG, IgG1 and IgG2a).

Procedure

5 **Animals** : BALB/c/Ola/HsD mice (Harland, Horst, Netherlands) : 24 mice.

Antigen : HpUreB 1-569, expressed as recombinant protein in *E. coli* (M15 strain, Qiagen, Hilden, GFR) according to a previously described method (Michetti et al., Gastroenterology, 107 : (1994) 1002).

Adjuvant : OM-294-DP (2.2 mg/ml stock solution)

10 **Immunization Regimen** :

Four groups containing 6 mice each were formed :

Groups A : 6 BALB/c mice were immunized four times by nasal administration of 25 µg of OM-294-DP alone (25 µl per dose) once a week throughout 4 consecutive weeks.

15 **Group B** : 6 BALB/c mice were immunized four times by nasal administration of 50 µg of Ure B 1-569 + 25 µg OM-294-DP (25 µl per dose) once a week throughout 4 consecutive weeks

Two weeks after the last nasal route immunization, blood was sampled by tail puncture from each mouse in groups A & B.

20 **Assay for serum IgG** :

Coating buffer (pH 9.6) : per 1 liter, Na₂CO₃ (15 mM, 1.59 g), NaHCO₃ (34.8 mM, 2.93 g), Thimerosal (0.01%); **PBS-Tween Buffer pH 7.4** : per 1 liter, NaCl (137 mM, 8.0 g), KH₂PO₄ (1.5 mM, 0.2 g), Na₂HPO₄ (8.0 mM, 1.15 g), KCl (2.7 mM, 0.2 g), Tween 20 (0.1% 1 ml);
25 **Citrate/phosphate buffer pH 5.0** : per 1 liter, citric acid (44.4 mM, 9.32 g), Na₂HPO₄ (103 mM, 14.6 g); **Substrate solution 10x** (O-phenyldiamine = OPD) (10-fold concentrated.) : (10 mg/ml in citrate buffer); **Sodium azide solution** : 1%, **Stop solution** : 0.01% sodium azide in citrate/phosphate buffer 0.1 M pH 5.0

30 **Method** : An antigen solution (UreB 1-569 prepared on May 26th, 1999, 0.5 mg/ml stock solution) is prepared at a concentration of 5 µg/ml in coating buffer pH9.6 (500 µl of UreB solution per 50 ml of buffer). 100 µl are pipetted into each well in 3 round bottom 96-well plates (0.5 µg UreB per well). The plates are incubated for 2 hours at 37°C. Supernatant fluids
35 are discarded from the plates. Wells are blocked by adding 100 µl of PBS-

0.1% Tween solution + 5% milk powder per well. Plates are incubated for 30 minutes at 37°C. The blocking solution is discarded and wells are washed 3 times with 100 µl of PBS-Tween. Supernatant fluids are discarded. A 1:200 dilution of each mouse serum to be tested is prepared in PBS- 0.1% Tween buffer (5 µl of serum in 1 ml of PBS-Tween). Sera (100 µl) are divided in duplicates into three plates (1 plate to detect total IgG, 1 plate to detect IgG1 and 1 plate to detect IgG2a). Incubation is carried out overnight at 4°C. Wells are washed 3 times with 100 µl of PBS-Tween. A 1:500 dilution of biotin-coupled- anti-IgG total antibody (Amersham, Cat # RPN 1177), anti-IgG1 antibody (Amersham Cat # RPN 1180) and anti-IgG2a antibody solutions (Pharmingen Cat #~02012D) in PBS-Tween buffer is individually prepared. 100 µl of the anti-IgG total antibody solution are added to plate N° 1, 100 µl of the anti-IgG1 solution to plate N° 2 and 100 µl of the anti-IgG2a antibody solution to plate N° 3. Incubation is carried out for 1 hour at 37°C. Wells are washed 3 times with PBS-Tween. A 1 :1000 dilution of streptavidin-HRP (Dako, Cat # p0397) is prepared in PBS-Tween buffer and 100 µl of the solution are added per well. Incubation is carried out for 1 hour at 37°C. The wells are washed 3 times with PBS-Tween buffer. A substrate solution is prepared by diluting 10-fold the OPD solution (10x) in 0.1 M citrate/phosphate buffer. 1 µl of H₂O₂ is added to the dilute OPD solution. 50 µl of the substrate solution are added to each well. Color development is allowed to occur for 10 to 20 minutes. The reaction is terminated by adding 50 µl of stop buffer. Absorbance is read at 492 nm (with a standard being read at 620 nm) using a negative control as blank.

Statistical analysis : Data stand for mean \pm SD (n=6). p values are derived from t-Student test. Data significance level is set at $p < 0.05$.

Results

Previously immunized mice with UreB-1-569+ OM-294-DP through nasal route administration develop an anti-UreB humoral immunity : anti-UreB 1-569 IgG1 are present in the blood.

Presence of antibodies specifically directed against UreB of *Hp* in mouse serum is measured by ELISA. UreB (0.5 µg/well) is dispensed into round bottom 96-well plates together with carbonate buffer pH 9.6. Specific antibodies are detected by means of rabbit anti-IgG total antibodies, anti-

IgG1 and IgG2a antibodies. Results are given as optical density (OD) reading at 492 nm. OD values 3 times greater than measured values in serum of naive mice are considered positive. No anti-UreB antibodies are detected in the serum of mice immunized with OM-294-DP alone. Mice which have been immunized with Ure+OM-294-DP also develop total anti-UreB IgG antibodies ($OD = 0.274 \pm 0.130$, $p < 0.05$) and anti-UreB IgG1 ($OD = 0.212 \pm 0.128$, $p < 0.05$), but do not develop anti-UreB IgG2a antibodies ($OD = 0.008 \pm 0.005$, non significant).

BALB/c mice immunized with urease B subunit of *Helicobacter pylori* by nasal administration (UreB) + OM-294-DP develop an anti-UreB humoral response mainly of the IgG1 type. OM-294-DP can therefore act as an adjuvant by nasal route administration and promote development of a humoral immunity of the Th2 type.

12. OM-294-MP and OM-294-DP in combination with H1N1 antigen : Determining specific antibodies raised in mice after 1 or 2 subcutaneous administrations

Procedure

This study is aimed at demonstrating the adjuvant effect of OM-294-MP and OM-294-DP for influenza antigen H1N1 (262195 A/B Beijing haemagglutinin, Solvay Duphar, Weesp, NL). To this end, 60 BALB/c mice (females, 8 weeks-old at the beginning of treatment) are divided into 6 groups as follows :

Groups	Antigen Final conc. : 2.5 µg per animal/injection	Adjuvants Final conc. : 50 µg per animal/injection	NaCl (0.9%)	Injected volume
A : NaCl	-	-	150 µl	150 µl
B : H1N1	H1N1 (100 µl)	-	50 µl	150 µl
C : H1N1+ OM-294-MP	H1N1 (100 µl)	OM-294-MP (50 µl)	-	150 µl
D : H1N1+ OM-294-DP	H1N1 (100 µl)	OM-294-MP (50 µl)	100 µl	150 µl
E : OM-294-MP	-	OM-284-MP (50 µl)	100 µl	150 µl
F : OM-294-DP	-	OM-284-DP (50 µl)	100 µl	150 µl

Antigen : H1N1 stock solution is prepared at a concentration of 25 µg/ml in 0.9% NaCl.

Adjuvants : Stock solutions of OM-294-DP and OM-294-MP are prepared at a concentration of 1 mg/ml in injection water, with 0.1% triethanolamine being added to OM-294-MP. The negative control consists of a 0.9% NaCl solution without antigen.

Antigen-adjuvant mixture : Adjuvants are kept for 20 minutes at 37°C before vortexing for 3 minutes. Then, the antigen and NaCl (0.9%) are added as stated in the Table given above, and the antigen-adjuvant mixture is vortexed briefly before placing it on a rotary stirrer for 15 minutes at room temperature, and finally the whole mixture is vortexed for 3 minutes.

Immunization regimen : Injections are scheduled on days 0 and 14. Mixtures indicated in the aforementioned Table are administered by subcutaneous route (75 µl on the side, with a total 150 µl per animal). Blood sampling is scheduled on days 14 and 18 (orbital punctures).

Assay for anti-H1N1 immunoglobulins : The following serum Immunoglobulins which are specifically directed against H1N1 are assayed in duplicate by ELISA : IgG1, IgG2a, and IgM. Briefly stated, microtiter plates (NUNC Immunoplate, Roskilde, DK) are incubated (overnight

coating) at 4°C with 100 µl H1N1 (0.5 µg) in bicarbonate buffer pH 9.6). After washing with 0.5% Tween-20 (Merck Hohenbrunn, D), sera are diluted 50-, 200- and 800-fold (diluting solution : phosphate buffered saline (PBS) + 1% bovine serum albumin (BSA, Sigma, St. Louis, MO, USA) + 0.02% Tween-20)). 100 µl of each dilute serum sample are added to the wells. Incubation lasts 45 minutes at 37°C.

After a second washing step, IgG1, IgG2a and IgM specifically directed to H1N1 are incubated for 30 minutes at 37°C together with 100 µl of anti-IgG1 antibodies (anti-mouse rat antibody)-peroxydase conjugate (Serotec, Oxford, UK), IgG2a-peroxydase conjugate (Pharmingen, San Diego, CA, USA) and IgM-biotin conjugate (Pharmingen, San Diego, CA, USA), diluted beforehand in PBS/BSA/Tween buffer (250-, 1000-, 500-fold dilutions, respectively). For IgM, after an extra washing step, a 3rd incubation is required (30 min. at 37°C) with a 1:100 dilute solution of streptavidin-peroxydase conjugate (Dako, Glostrup, DK).

After the washing step, 100 µl of a phenylene 1,2-diamine solution (OPD, Merck, Darmstadt, GFR) are added to detect peroxydase-coupled anti-IgG1 and anti-IgG2 secondary antibodies (whereas for IgM, the reagent being used is 3', 3', 5', 5'-tetramethylbenzidine (TMB, Sigma, St. Louis, MO, USA). After a 20 minute incubation period at room temperature, the reaction is stopped by adding 100 µl of 2N H₂SO₄. Absorbance values are read at 490 nm with a Bio-Rad 3550 model plate reader.

Results

Results of each reading at 490 nm are given in arbitrary units (A.U.) per ml. This is achieved by comparing each sample with a standard prepared from variable dilutions of a sample pool collected from group B (animals injected with H1N1 alone) at day 28. As the term implies, the sample pool diluted 50-fold is at a concentration of 1000 A.U./ml. Individual results are then corrected for the corresponding dilution factor (50, 200, or 800 times). Only the mean values of each group and the standard deviation (SD) are herein reported.

Table a) Immunoglobulins specifically raised against H1N1 of IgG1 subclass (Arbitrary units/ml \pm SD, ** p < 0.01 (Anova & (two sided) Dunnetts tests).

Groups	Day 14	Day 28
A : NaCl	3 \pm 5	0 \pm 0
B : H1N1	11161 \pm 5755	53950 \pm 23403
C : H1N1 + OM-294-MP	34411 \pm 13719	228467** \pm 109123
D : H1N1 + OM-294-DP	30101 \pm 19061	382325** \pm 201314
E : OM-294-MP	69 \pm 34	59 \pm 31
F : OM-294-DP	59 \pm 21	38 \pm 25

5

Table b) Immunoglobulins specifically raised against H1N1 of IgG2a subclass (Arbitrary units/ml \pm SD, ** p < 0.01 (Anova & (two sided) Dunnetts tests).

Groups	Day 14	Day 28
A : NaCl	0 \pm 0	0 \pm 0
B : H1N1	26883 \pm 20779	50352 \pm 30846
C : H1N1 + OM-294-MP	179344** \pm 139781	1622722** \pm 986195
D : H1N1 + OM-294-DP	103630 \pm 96257	681441 \pm 1072710
E : OM-294-MP	1619 \pm 743	1767 \pm 1034
F : OM-294-DP	452 \pm 584	782 \pm 857

10

Table c) Immunoglobulins specifically raised against H1N1 of IgM subclass (Arbitrary units/ml \pm SD, *p < 0.05 & **p < 0.01 (Anova & (two sided) Dunnetts tests).

Groups	Day 14	Day 28
A : NaCl	22102+5862	21531+3693
B : H1N1	37787+15001	57306+26886
C : H1N1 + OM-294-MP	67936**+21334	95108+38669
D : H1N1 + OM-294-DP	598100*+18324	92920+26971
E : OM-294-MP	19065+4069	18018+1016
F : OM-294-DP	20756+7160	20944+9065

These results indicate that OM-294-MP and OM-294-DP adjuvants are active in the model under investigation, since they both significantly increase the titer of antibodies specifically raised against H1N1 in mice after one or two injections (see Figures 22, 23, 24), irrespective of the immunoglobulin subclass being considered (IgG1a, IgG2a and IgM).

13. OM-294-OM and OM-294-DP in combination with ovalbumin antigen : Determining specific antibodies raised in mice after 1 or 2 subcutaneous administrations

Procedure

This study is aimed at demonstrating the adjuvant effect of OM-294-MP and OM-294-DP with regard to ovalbumin antigen (Fluka Chemie, Buchs, Switzerland). To this end, 50 BALB/c mice (females, aged 8 weeks at the beginning of treatment) were divided into 5 groups as follows :

Groups	Antigen Final conc. : 50 µg per animal/injection	Adjuvants Final conc. : 50 µg per animal/injection	NaCl	Injected volume
A : NaCl	-	-	150 µl	150 µl
B : Ova	Ova (100 µl)	-	50 µl	150 µl
C : Ova + OM-294-MP	Ova (100 µl)	OM-294-MP (50 µl)	-	150 µl
D : Ova + OM-294-DP	Ova (100 µl)	OM-294-DP (50 µl)	-	150 µl
E : OM-294-MP	-	OM-294-MP (50 µl)	100 µl	150 µl

Antigen : An ovalbumin stock solution is prepared at a concentration of 0.5 mg/ml in 0.9% NaCl.

Adjuvants : Stock solutions of OM-294-DP and OM-294-MP are prepared at a concentration of 1 mg/ml in water for injection, with 0.1% triethanolamine being added for OM-294-MP. The negative control consists of a 0.9% NaCl solution without antigen.

5 Antigen-Adjuvant mixture : Adjuvants are allowed to stand for 20 minutes at 37°C before vortex treatment for 3 minutes. Then the antigen and (0.9%) NaCl are added as specified in the above Table, and the antigen/adjuvant mixture is vortexed briefly before placing it on a rotary stirrer for 15 minutes at room temperature, then the whole mixture is
10 vortexed for 3 minutes.

Immunization regimen : Injections are scheduled on days 0 and 14. The mixtures stated in the preceeding table are administered by subcutaneous route (75 µl on the side, 150 µl in total per animal). Blood sampling is scheduled on days 14 and 28 (orbital puncture).

15 Assay for anti-ovalbumin immunoglobulins : The following serum Immunoglobulins which are specifically directed against ovalbumin are assayed in duplicate by ELISA : IgG1, IgG2a, and IgM. Briefly stated, microtiter plates (NUNC Immunoplate, Roskilde, DK) are incubated (overnight coating) at 4°C together with 100 µl ovalbumin (0.5 µg) in
20 bicarbonate buffer pH 9.6). After washing with 0.5% Tween-20 (Merck Hohenbrunn, D), sera are diluted 50-, 200- and 800-fold (diluting solution : phosphate buffered saline (PBS) + 1% bovine serum albumin (BSA, Sigma, St. Louis, MO, USA) + 0.02% Tween-20)). 100 µl of each dilute serum sample are added to the wells. Incubation lasts 45 minutes at 37°C.

25 After a second washing step, IgG1, IgG2a and IgM specifically directed to ovalbumin are incubated for 30 minutes at 37°C together with 100 µl of anti-IgG1 antibodies (anti-mouse rat antibody)-peroxydase conjugate (Serotec, Oxford, UK), IgG2a-peroxydase conjugate (Pharmingen, San Diego, CA, USA) and IgM-biotin conjugate
30 (Pharmingen, San Diego, CA, USA), diluted beforehand in PBS/BSA/Tween buffer (250-, 1000-, 500-fold dilutions, respectively). For IgM, after an extra washing step, a 3rd incubation step is required (30 min. at 37°C) with a 1:100 dilute solution of streptavidin-peroxydase conjugate (Dako, Glostrup, DK).

After the washing step, 100 μ l of a phenylene 1,2-diamine solution (OPD, Merck, Darmstadt, GFR) are added to detect peroxidase-coupled anti-IgG1 and anti-IgG2 secondary antibodies (whereas for IgM, the reagent being used is 3', 3', 5', 5'-tetramethylbenzidine (TMB, Sigma, St. Louis, MO, USA). After a 20 minute incubation period at room temperature, the reaction is stopped by adding 100 μ l of 2N H₂SO₄. Absorbance values are read at 490 nm with a Bio-Rad 3550 model plate reader

Results

Results of each reading at 490 nm are given in arbitrary units (A.U.) per ml. This is achieved by comparing each sample with a standard prepared from different dilutions of a sample pool collected from group B at day 28 (animals injected with ovalbumin alone). As clearly understood by this term, the sample pool diluted 50-fold is at a concentration of 1000 A.U./ml. Individual results are then corrected for the corresponding dilution factor (50, 200, or 800 times). Only the mean values of each group and the standard deviation (SD) are herein reported.

Table a) Immunoglobulins specifically raised against ovalbumin of IgG1 subclass (Arbitrary units/ml \pm SD, ** p < 0.01 (Anova & (two sided) Dunnetts tests).

Groups	Day 14	Day 28
A : NaCl	6 \pm 6	16 \pm 12
B : ova	728 \pm 589	47743 \pm 46294
C : ova + OM-294-MP	4361** \pm 2513	284121** \pm 164822
D : ova + OM-294-DP	3240** \pm 1794	277025** \pm 173737
E : OM-294-MP	19 \pm 8	40 \pm 69

Table b) Immunoglobulins specifically raised against ovalbumin of IgG2a subclass (Arbitrary units/ml \pm SD, *p < 0.05 ** p < 0.01 (Anova & (two sided) Dunnetts tests).

Groups	Day 14	Day 28
A : NaCl	2996+898	5414+1554
B : ova	5201+1880	73162+107954
C : ova + OM-294-MP	9524+6809	625663*+681232
D : ova + OM-294-DP	18108**+14958	601434*+624166
E : OM-294-MP	11253+12169	4192+2104

5

Table c) Immunoglobulins specifically raised against ovalbumin of IgM subclass (Arbitrary units/ml \pm SD)

Groups	Day 14	Day 28
A : NaCl	14009+6158	12288+7136
B : ova	19423+13778	47998+34035
C : ova + OM-294-MP	21652+9524	38240+8822
D : ova + OM-294-DP	25762+10975	74399+119781
E : OM-294-MP	19742+5667	9827+2021

10 These results indicate that OM-294-MP and OM-294-DP adjuvants are active in the present model under investigation, since they both significantly increase (with respect to IgG1 and IgG2a subclasses) the titer of antibodies specifically raised against ovalbumin in mice after one or two injections (see Figures 25, 26, 27).

15 **14. OM-294-MP and OM-294-DP in combination with TT antigen (Tetanos toxoid) : Determining specific antibodies raised in mice after 1 or 2 subcutaneous administrations**

Procedure

20 This study is aimed at demonstrating the adjuvant effect of OM-294-MP and OM-294-DP for TT antigen (Massachussetts Biologic Laboratoires, MA, USA). To this end, 40 BALB/c mice (females, 8 weeks-old at the beginning of treatment) are divided into 4 groups as follows :

Groups	Antigen Final conc. : 50 µg per animal/injection	Adjuvants Final conc. : 50 µg per animal/injection	NaCl (0.9%)	Injected volume
A : NaCl	-	-	150 µl	150 µl
B : TT	TT (100 µl)	-	50 µl	150 µl
C : TT + OM-294-MP	TT (100 µl)	OM-294-MP (50 µl)	-	150 µl
D : TT + OM-294-MP	TT(100 µl)	OM-294-DP (50 µl)	-	150 µl

Antigen : A TT stock solution is prepared at a concentration of 0.2 mg/ml in 0.9% NaCl.

Adjuvants : Stock solutions of OM-294-DP and OM-294-MP are prepared at a concentration of 1 mg/ml in water for injection, with 0.1% triethanolamine being added for OM-294-MP. The negative control consists of a 0.9% NaCl solution without antigen.

Antigen-Adjuvant mixture : Adjuvants are allowed to stand for 20 minutes at 37°C before vortex treatment for 3 minutes. Then the antigen and (0.9%) NaCl are added as specified in the above Table, and the antigen/adjuvant mixture is vortexed briefly before placing it on a rotary stirrer for 15 minutes at room temperature, then the whole mixture is vortexed for 3 minutes.

Immunization regimen : Injections are scheduled on days 0 and 14. The mixtures stated in the preceeding table are administered by subcutaneous route (75 µl on the side, 150 µl in total per animal). Blood sampling is scheduled on days 14 and 28 (orbital puncture).

Assay for anti-TT immunoglobulins : The following serum Immunoglobulins which are specifically directed against TT are assayed in duplicate by ELISA : IgG1, IgG2a, and IgM. Microtiter plates (NUNC Immunoplate, Roskilde, DK) are incubated (overnight coating) at 4°C together with 100 µl TT (0.5 µg) in bicarbonate buffer (pH 9.6). After washing with 0.5% Tween-20 (Merck Hohenbrunn, D), sera are diluted 50-, 200- and 800-fold (diluting solution : phosphate buffered saline (PBS) + 1% bovine serum albumin (BSA, Sigma, St. Louis, MO, USA) + 0.02% Tween-20)). 100 µl of each dilute serum sample are added to the wells. Incubation lasts 45 minutes at 37°C.

After a second washing step, IgG1, IgG2a and IgM specifically directed to ovalbumin are incubated for 30 minutes at 37°C together with 100 µl of anti-IgG1 antibodies-peroxydase conjugate (Serotec, Oxford, UK), IgG2a-peroxydase conjugate (Pharmingen, San Diego, CA, USA) and IgM-biotin conjugate (Pharmingen, San Diego, CA, USA), diluted beforehand in PBS/BSA/Tween buffer (250-, 1000-, 500-fold dilutions, respectively). For IgM, after an extra washing step, a 3rd incubation step is required (30 min. at 37°C) with a 1 : 100 dilute solution of streptavidin-peroxydase conjugate (Dako, Glostrup, DK).

After the washing step, 100 µl of a phenylene 1,2-diamine solution (OPD, Merck, Darmstadt, GFR) are added to detect peroxydase-coupled anti-IgG1 and anti-IgG2 secondary antibodies (whereas for IgM, the reagent being used is 3', 3', 5', 5'-tetramethylbenzidine (TMB, Sigma, St. Louis, MO, USA). After a 20 minute incubation period at room temperature (40 min. for TMB), the reaction is stopped by adding 100 µl of 2N H₂SO₄. Absorbance values are read at 490 nm with a Bio-Rad 3550 model plate reader

Results

Results of each reading at 490 nm when measuring IgG1 and IgG2a are given in arbitrary units (A.U.) per ml. This is achieved by comparing each sample with a standard prepared from different dilutions of a sample pool collected from the group B at day 28 (animals injected with TT alone). As this term implies, the sample pool diluted 50-fold is at a concentration of 1000 A.U./ml. Individual results are then corrected for the corresponding dilution factor (50, 200, or 800 fold). Only the mean values of each group and the standard deviation (SD) are herein reported.

Regarding the assay of IgM specific for TT, since the "background noise" of the assay was too high, no clear cut difference could be found between group B (TT alone) and groups C and D (TT with adjuvant) by measuring specific IgM as previously done for IgG1 and IgG2a. Instead, specific IgM titer could be determined, using successive dilutions of each sample (rather than A.U. described before) and the result was reported, for each sample, as the highest dilution which gives an absorbance reading greater than mean absorbance \pm 3 SD for group A (NaCl). The titer thus obtained indicates the number of times a serum sample can be diluted

before the absorbance thereof could no longer be distinguished from background noise level. This final dilution is the result reported in Table (c) for IgM given hereinafter.

- 5 Table (a) Immunoglobulins specifically raised against TT of IgG1 subclass (Arbitrary units/ml \pm SD, ** p < 0.01 (Anova & (two sided) Dunnetts tests)).

Groups	Day 14	Day 28
A : NaCl	1 \pm 2	0 \pm 1
B : TT	2871 \pm 1633	34367 \pm 15018
C : TT + OM-294-MP	8502 ^{**} \pm 2020	78506 ^{**} \pm 21660
D : TT + OM-294-DP	11620 ^{**} \pm 2348	136463 ^{**} \pm 41025

- 10 Table (b) Immunoglobulins specifically raised against TT of IgG2a subclass (Arbitrary units/ml \pm SD, **p < 0.01 (Anova & (two sided) Dunnetts tests)).

Groups	Day 14	Day 28
A : NaCl	351 \pm 506	536 \pm 1046
B : TT	2547 \pm 2539	61387 \pm 82269
C : TT + OM-294-MP	8869 \pm 6979	65881 \pm 46635
D : TT + OM-294-DP	21969 ^{**} \pm 25067	148365 \pm 134196

Table (c) Titer of immunoglobulins specifically directed against TT of IgM subclass (dilutions for each sample giving a signal at 490 nm greater than the mean \pm 3 SD for a sample dilution in group A).

Groups	Day 14	Day 28
A : NaCl	standard	standard
B : TT	9 animals < 25 1 animal < 50	10 animals < 25
C : TT + OM-294-MP	9 animals < 25 1 animal > 1600	7 animals < 25 1 animal < 100 2 animals > 1600
D : TT + OM-294-DP	7 animals < 25 1 animal < 200 2 animals > 1600	10 animals < 25

5

These results indicate that adjuvants OM-294-MP and OM-294-DP are active in the present model under investigation, since they both often significantly increase the titer of IgG1 and IgG2a antibodies specifically raised against TT in mice after one or two injections (see Figures 28, 29). By contrast, only a few animals produced IgM specific to TT.

10

15. Evaluation of the adjuvant properties of OM-294-MP in a CBA mouse immunization model by subcutaneous administration of *Leishmania* gp63 antigen.

Procedure

15

CBA mice are administered in the tail two subcutaneous injections of gp63 at a dose of 2 μ g at intervals of 8 days. OM-294-MP adjuvant is mixed with both doses of antigen, BCG is mixed only with the first dose. Each mouse is administered 2 x 50 μ g of OM-294-MP or 200 μ g of BCG. A control group is injected with antigen alone (without adjuvant). Ten days after the second injection, the inguinal and periaortic lymph node cells (groups of 3 mice each) are cultured and the proliferation response to the purified gp63 antigen is assayed by measuring (3 H-TdR) thymidine take-up. *In vitro* cytokine production in terms of γ IFN and IL-4 by secreted by lymph node lymphocytes rechallenged *in vitro* with the gp63 antigen is also determined by ELISA (MIF100 IFN and M4000 IL-4 kits, R&D Systems,

25

Europe Ltd., Abingdon, UK) on each supernatant sample of lymph node lymphocyte culture prior to the addition of ^3H -TdR.

Values reported in the tables for ^3H -TdR take-up, stand for the arithmetic mean \pm standard deviation (triplicates) expressed in cpm and values relating to cytokines in the supernatant fluid correspond to the arithmetic mean \pm standard deviation (triplicates) expressed in pg per ml.

Antigen : A gp63 stock solution is prepared at a concentration of 40 $\mu\text{g/ml}$ in 0.9% NaCl.

Adjuvants : The stock solution of OM-294-MP is prepared at a concentration of 1 mg/ml in water for injection, with addition of 0.1% triethanolamine. The negative control consists of a PBS solution without antigen.

Antigen-Adjuvant mixture : Adjuvants are allowed to stand for 10 minutes at 37°C before vortex treatment for 3 minutes. Then, the antigen (1 volume) and the adjuvant (1 volume) are mixed and vortexed briefly before incubation for 20 minutes at 37°C , and finally the whole mixture is vortexed for 3 minutes.

Results

In mice immunized with gp63 antigen, OM-294-MP adjuvant induces a better lymphocyte proliferation response (table (a) and Figure 30 (a)) than BCG. In fact, with respect to cultures from animals that have been immunized without adjuvant, the increase in proliferation rate ranges from 3.1 to 6 folds for OM-294-MP product while it does not exceed 3.5 folds for BCG (2.6 - 3.5).

In those lymphocyte cultures, cytokine production is measured in the supernatant fluid (Table (b) and Figure (30 (b))). It is noted that antigen gp63 induces γ IFN secretion in quantities equivalent to mice treated by OM-294-MP or BCG as adjuvant. By contrast, OM-294-MP adjuvant seems to favor secretion of substantial quantities of IL-4 by (anti-gp63) immune lymphocytes while BCG treated murine lymphocytes secrete minor or even undetectable quantities of said cytokine.

Table (a) Effect of OM-294-MP adjuvant on immune response against gp63 antigen, as measured by murine T lymphocyte proliferation in response to gp63 antigen *in vitro*

gp63 <i>in vitro</i> ($\mu\text{g/ml}$)	without adjuvant (cpm $\times 10^{-3}/\text{ml}$)	OM-294-MP (cpm $\times 10^{-3}/\text{ml}$)	BCG (cpm $\times 10^{-3}/\text{ml}$)
0	1.4 \pm 0.4	2.8 \pm 0.7	5.3 \pm 1.1
0.16	18 \pm 5	65 \pm 11	47 \pm 9
0.31	17 \pm 5	92 \pm 11	57 \pm 17
0.62	16 \pm 4	93 \pm 13	54 \pm 13
1.25	13 \pm 2	39 \pm 7	44 \pm 9

5

Values reported in Table (a) stand for the arithmetic mean take-up \pm standard deviation (triplicate cultures)

Table (b) Effect of OM-294-MP adjuvant administered *in vivo* in conjunction with gp63 antigen on *in vitro* production of cytokines by lymph node lymphocytes

10

γ IFN concentration (pg/ml)			
gp63 <i>in vitro</i>	without adjuvant	294-MP	BCG
0	< 9	< 9	27
0.3	78	135	200
0.6	38	120	105
IL-4 concentration (pg/ml)			
gp63 <i>in vitro</i>	without adjuvant	294-MP	BCG
0	< 8	< 8	< 8
0.3	< 15	125	15
0.6	< 8	83	< 8

15

OM-294-MP adjuvant potentiates specific T response *in vitro* in CBA mice which have been immunized with gp63 (an amphophilic antigen of the *Leishmania* parasite) as assayed by lymphocyte proliferation and antigen-induced γ IFN and IL-4 production.

16. Effectiveness of OM-294-MP adjuvant during anti-LmCPb T-primary response in a CBA mouse-based immunization model when administered by subcutaneous route with *Leishmania mexicana* LmCPb antigen

5

Procedure

CBA mice were administered through the tail a single injection of LmCPb in a 2 µg dose either in combination or not with 50 µg of OM-294-MP adjuvant. A control group was administered one injection of physiological saline buffer (non immunized subjects). Eleven days later, cells of the inguinal and periaortic lymph nodes (groups of 3 mice each) were cultured and the proliferative response directed to the purified LmCPb antigen, to a preparation of whole amastigotes of *Leishmania mexicana* and to concanavalin A (ConA) was evaluated by measuring tritiated thymidine take-up (^3H -TdR). γ IFN and IL-4 cytokine production by lymph node lymphocytes rechallenged *in vitro* with LmCPb antigen of *Leishmania mexicana* or by amastigotes was equally determined by ELISA (MIF00 γ IFN & M4000 IL-4 kits, R&D Systems Europe Ltd, Abingdon, UK) using a sample of each culture supernatant of lymph node lymphocytes before addition of ^3H -TdR.

20

Values reported in the tables stand for the mean value \pm standard deviation (triplicate) expressed in cpm for ^3H -TdR take-up and the arithmetic mean \pm standard deviation (triplicate) expressed in pg per ml for cytokine production in supernatant fluids.

25

Antigen : LmCPb stock solution is prepared at a concentration of 40 µg/ml in PBS (2x).

Adjuvants : OM-294-MP stock solution is prepared at a concentration of 1 mg/ml in water for injection with addition of 0.1% triethanolamine. The negative control consists of a PBS solution without antigen.

30

Antigen-adjuvant mixture : Adjuvants are maintained for 10 minutes at 37°C before vortexing for 3 minutes. Then, the antigen (1 volume) and the adjuvant (1 volume) are mixed and vortexed briefly before being incubated for 20 minutes at 37°C, and finally the whole mixture is vortexed again for 3 minutes.

Results

In absence of any stimulus in the culture medium, OM-294-MP adjuvant promotes development of lymphocytes which undergo spontaneous proliferation (Table (a) and Figure 31 (a)) and secrete trace amounts of γ IFN (Table (b) and Figure 31(b)). This reaction is strongly potentiated when purified LmCPb antigen or an extract of whole parasite is added to the cultures. In this experiment, the adjuvant is observed to exert a clear influence on the induction of sensitized lymphocytes (anti-LmCPb) able to secrete substantial quantities of IL-4 (Table (b) and Figure 31 (b)).

10

Table (a) *in vitro* proliferative response of lymph node cells immunized *in vivo* by LmCPb : effect of OM-294-MP adjuvant

Antigen <i>in vitro</i>	³ H-TdR take-up (cpm x 10 ⁻³ /ml)		
	Non immunized	Without adjuvant	OM-294-MP
No stimulant	0.9 \pm 0.3	2.2 \pm 0.7	11 \pm 2
LmCPb 0.6 μ g/ml	0.8 \pm 0.4	1.7 \pm 0.1	19 \pm 4
LmCPb 1.7 μ g/ml	0.9 \pm 0.1	4.6 \pm 1.6	40 \pm 4
LmCPb 5 μ g/ml	1.3 \pm 0.8	7.2 \pm 0.6	80 \pm 5
LmCPb 15 μ g/ml	2.6 \pm 0.4	16.2 \pm 2.1	140 \pm 10
Amastigotes 1.9 x 10 ⁻⁶ /ml	0.8 \pm 0.2	1.7 \pm 0.1	44 \pm 7
Amastigotes 6 x 10 ⁻⁶ /ml	1.5 \pm 0.2	4.6 \pm 0.6	79 \pm 6
Amastigotes 17 x 10 ⁻⁶ /ml	2.9 \pm 0.6	7.2 \pm 0.6	119 \pm 4
Con A 5 μ g/ml	123 \pm 33	193 \pm 17	196 \pm 10

Table (b) *In vitro* secretion of cytokines by lymph node lymphocytes immunized *in vivo* by LmCPb : Effect of OM-294-MP adjuvant on primary response

γ IFN production(pg/ml)			
<i>In vitro</i> stimulant	Non immunized	without adjuvant	OM-294-MP
No stimulant	< 9	< 9	25
LmCPb 15 μ g/ml	< 9	46	480
Amastigotes 17 x 10 ⁻⁵ /ml	< 9	95	320
Con A 5 μ g/ml	> 1800	> 1800	> 1800
IL-4 production (pg/ml)			
<i>In vitro</i> stimulant	Non immunized	without adjuvant	OM-294-MP
No challenge	< 8	< 8	< 8
LmCPb 15 μ g/ml	< 8	< 8	130
Amastigotes 17 x 10 ⁻⁵ /ml	< 8	< 8	65
Con A 5 μ g/ml	92	190	360

5

OM-294-MP adjuvant is also very effective during the primary T-response (following a single vaccine injection). Properties of the adjuvant effect on this response (increase of lymphocyte proliferation, induction of cytokine production) are similar to those observed during the response to two vaccine injections.

10

17. Evaluation of OM-294-MP and OM-294-DP adjuvant properties in CBA mouse-based immunization model through subcutaneous administration of *Leishmania mexicana* LmCPb antigen : comparison with BCG

15

Procedure

20

CBA mice (8 mice per group) were administered in the tail 2 subcutaneous injections of 3 - 5 μ g of purified LmCPb at intervals of 8 days. OM-294-MP and OM-294-DP adjuvants were mixed with both doses of antigen, whereas BCG was only mixed with the first one. Each mouse received 2 x 50 μ g of OM adjuvant or 200 μ g of BCG. Eight days following the second injection, the periaortic and inguinal lymph nodes (3 mice per

group) are removed and the cells are cultured in order to assay the proliferative response to purified LmCPb antigen, or respectively, the proliferative response to a whole preparation of *Leishmania mexicana* amastigotes or to Concanavalin A (Con A). The proliferative response is evaluated by measuring tritiated thymidine take-up (^3H -TdR). γ IFN and IL-4 cytokine production by lymph node lymphocytes rechallenged *in vitro* by the LmCPb antigen of *Leishmania mexicana* or by the amastigotes or by Con A is determined by ELISA (MIF00 γ IFN & M4000 IL-4 kits, R&D Systems Europe Ltd., Abingdon, UK) using a sample of each culture supernatant of lymph node lymphocytes before addition of ^3H -TdR.

Values reported in the tables stand for the arithmetic mean \pm standard deviation expressed in % of standard regarding antibody titer, the arithmetic mean \pm standard deviation (triplicates) expressed in cpm for ^3H -TdR take-up, and the arithmetic mean \pm standard deviation (triplicates) expressed in pg per ml for cytokine production.

Antigen : LmCPb stock solution is prepared at a concentration of 60 -100 $\mu\text{g/ml}$ in 0.9% NaCl.

Adjuvants : OM-294-MP and OM-294-DP stock solutions are prepared at a concentration of 1 mg/ml in water for injection with addition of 0.1% triethanolamine for OM-294-MP. The negative control consists of a PBS solution without antigen.

Antigen-adjuvant mixture : Adjuvants are maintained for 10 minutes at 37°C before vortexing for 3 minutes. Then, the antigen (1 volume) and the 0.9% adjuvant (1 volume) are mixed and vortexed briefly before being incubated for 20 minutes at 37°C , and finally the whole mixture is vortexed again for 3 minutes.

Results

In mice immunized with LmCPb antigen (Tables (a) and (b), Figures 32 (a) and (b)), the products OM-294-MP and OM-294-DP produce a similar effect to that observed in mice which develop an immune response against gp63. Therefore, in presence of LmCPb (15 $\mu\text{g/ml}$), the extent of proliferation of cultures derived from mice which have been immunized with antigen plus OM-294-MP and OM-294-DP adjuvants is respectively 23 and 28 times higher than cultures originating from mice administered antigen alone (without adjuvant). The impact of BCG in these conditions is smaller,

since the increase in proliferation is merely 11 fold. Analogous effects are seen in cultures challenged with purified antigen or a whole extract of *Leishmania* parasite, and for all antigen concentrations being tested.

γ IFN production in response to LmCPb antigen tends to be a bit higher with product OM-294-DP than with BCG (Table (b) and Figure 32 (b)). It shall be noted that in this experiment, lymphocytes proliferate and secrete substantial amounts of γ IFN even though the antigen might not have been added to the culture medium. In this case, OM-294-DP adjuvant tends to be somewhat more effective than BCG. A clear difference between OM-294-MP, OM-294-DP and BCG adjuvants respectively is observed as reported above regarding the development of lymphocytes able to produce IL-4. The quantity of IL-4 being produced under the influence of OM-294-MP and OM-294-DP adjuvants is significant since it matches the quantity secreted by lymphocytes exposed to Con A, a powerful non specific stimulant for lymphocytes (see Table (a) and (b)).

Table (a) *In vitro* proliferative response to lymph node cells derived from mice immunized *in vivo* with LmCPb : effect of different adjuvants

<i>in vitro</i> stimulant	³ H-TdR take-up (cpm x 10 ⁻³ /ml)			
	without adjuvant	OM-294-DP	OM-294-MP	BCG
No stimulant	1.7±0.6	21.8±2.2	17.1±2.5	18.6±4.8
LmCPb 0.6 µg/ml	0.8±0.3	40.9±12.7	22.9±2.8	19.0±7.4
LmCPb 1.7 µg/ml	2.4±0.1	57.2±10.9	34.1±4.1	39.8±5.7
LmCPb 5 µg/ml	2.8±0.6	70.2±9.2	70.3±6.4	44.0±10.4
LmCPb 15 µg/ml	4.3±0.1	100.0±6.5	124.2±12.0	46.2±0.3
Amastigotes 2 x 10 ⁻⁶ /ml	2.4±0.6	61.0±1.7	28.4±8.3	24.4±4.3
Amastigotes 6 x 10 ⁻⁶ /ml	2.3±0.7	81.5±5.5	66.1±4.5	23.6±2.5
Amastigotes 17 x 10 ⁻⁶ /ml	1.7±0.4	78.2±7.8	68.7±2.3	23.4±4.0
Con A 5 µg/ml	188.1±21.0	135.9±3.7	151.4±3.7	119.7±28.5

Values reported in the table stand for the arithmetic mean ± standard deviation in terms of tracer take-up (triplicate cultures)

Table (b) *in vitro* cytokine production by lymph node lymphocytes from mice immunized *in vivo* by LmCPb antigen : Effect of different adjuvants

γ IFN concentration (pg/ml)				
<i>In vitro</i> stimulant	without adjuvant	OM-294-DP	OM-294-DP	BCG
No stimulant	< 9	460	240	280
LmCPb 15 μ g/ml	44	520	360	460
Amastigotes 17×10^{-6} /ml	14	> 600	> 600	480
Con A 5 μ g/ml	1200	1200	1900	> 3000
IL-4 concentration (pg/ml)				
<i>In vitro</i> stimulant	without adjuvant	OM-294-DP	OM-294-DP	BCG
No stimulant	< 15	< 8	< 8	< 8
LmCPb 15 μ g/ml	< 15	110	88	36
Amastigotes 17×10^{-6} /ml	< 8	130	110	29
Con A 5 μ g/ml	40	230	85	105

- 5 OM-294-MP and OM-294-DP adjuvants potentiate efficiently the immune response against a soluble antigen of *Leishmania*, LmCPb protease. This is reflected *in vitro* by an increase in proliferative response followed by induction of γ IFN and IL-4 production in significant amounts.

10 EXAMPLE VI

Aqueous solution for injection

Compound of example III	1 g
Polysorbate 80	0.2 g
Sodium chloride	9 g
Distilled water for injection q.s.	1000 ml

- 15 The solution was adjusted to pH 7.5 with 0.1 M HCl and then was sterilized by membrane filtration on a 0.22 μ m Steritop Express 1000 membrane (PES membrane, 90 mM, SCGP T10 RE, Millipore Corporation, Bedford, MA, USA). The sterile solution was divided into sterile ampuls of 1 ml.


Lyophilized product

Compound of example IV	2 g
Polysorbate 80	0.2 g
Sodium chloride	9 g
Mannitol	10 g
Ascorbic acid	0.1 g
Distilled water for injection q.s.	1000 ml

The solution was adjusted to pH 7.4 with 0.1M HCl , then sterilized
5 by membrane filtration through a 0.22 μ l Steritop Express 1000 membrane
(PES membrane, 90 mm, SCGP T10 RE, Millipore Corporation, Bedford,
MA, USA). The sterile solution was divided into sterile multidose vials by
dispensing 1 ml per vial, and then freeze-dried.

WHAT IS CLAIMED IS

1. N-acyl-dipeptide-like compounds having the general formula I :



(I)

wherein R_1 and R_2 each designate an acyl group derived from a saturated or unsaturated, straight or branched chain-carboxylic acid having from 2 to 24 carbon atoms, which is unsubstituted or bears one or more substituents selected from the group comprised of hydroxyl, alkyl, alkoxy, acyloxy, amino, acylamino, acylthio and $((C_{1-24})\text{alkyl})\text{thio}$ groups,

subscripts m , p and q are integers ranging from 1 to 10,

subscript n is an integer ranging from 0 to 10,

X and Y each designate a hydrogen or an acid group selected among the groups listed below :


- carboxy $[(C_{1-5})\text{alkyl}]$
- $\text{CH}-[(\text{CH}_2)_m\text{COOH}] [(\text{CH}_2)_n\text{COOH}]$ with $m = 0$ to 5 and $n = 0$ to 5
- phosphono $[(C_{1-5})\text{alkyl}]$
- dihydroxyphosphoryloxy $[(C_{1-5})\text{alkyl}]$
- dimethoxyphosphoryl
- phosphono
- hydroxysulfonyl
- hydroxysulfonyl $[(C_{1-5})\text{alkyl}]$
- hydroxysulfonyloxy $[(C_{1-5})\text{alkyl}]$

either in neutral or charged form,

provided that at least one of substituents X and Y designates an acid group as specified above, either in neutral or charged form, A and B designate independantly from each other an oxygen atom, a sulfur atom or an imino group -NH-.

2. The salts of compounds of general formula I in accordance with claim 1, where X and/or Y are an acid group, made into salt form with a mineral or organic base, preferably one intended for therapeutic use.

wherein
or 2 viz.



(I')

wherein R_1 and R_2 each designate an acyl group derived from a saturated or unsaturated, straight or branched chain-carboxylic acid having from 2 to 24 carbon atoms, which is unsubstituted or bears one or more substituents selected from the group comprised of hydroxyl, alkyl, alkoxy, acyloxy, amino, acylamino, acylthio and $((C_{1-24})\text{alkyl})\text{thio}$ groups,

subscripts m , p and q are integers ranging from 1 to 10,

subscript n is an integer ranging from 0 to 10,

X and Y each designate a hydrogen atom or a phosphono group.

4. A compound in accordance with anyone of claims 1 to 3 viz. 3-(3-dodecanoyloxytetradecanoylamino) 9-(3-hydroxytetradecanoylamino)4-oxo-5-azadecan-1, 10-diol 1 and/or 10-dihydrogenphosphate and its addition salts formed with an organic or a mineral base.

5. A compound in accordance with anyone of claims 1 to 3, viz. 3-(3-dodecanoyloxy-tetradecanoylamino) 9-(3-hydroxytetradecanoylamino)4-oxo-5-azadecan-1, 10-diol 1,10-bis-(dihydrogenphosphate) and its addition salts formed with an organic or a mineral base.


6. A compound in accordance with anyone of claims 1 to 3, viz. 3-(3-hydroxytetradecanoylamino) 9-(3-dodecaoyloxytetradecanoylamino)4-oxo-5-azadecan-1, 10-diol 1,10-bis-(dihydrogenphosphate) and its addition salts formed with an organic or a mineral base.

7. A compound in accordance with anyone of claims 1 to 3, viz. 3-(3-dodecanoyloxytetradecanoylamino) 9-(3-hydroxytetradecanoylamino)4-oxo-5-azadecan 1, 10-diol mono 1-dihydrogenphosphate and its addition salts formed with an organic or a mineral base.

8. A compound in accordance with anyone of claims 1 to 3, viz. 3-(3-hydroxytetradecanoylamino) 9-(3-dodecanoyloxytetradecanoylamino)4-oxo-5-azadecan-1, 10-diol mono 1-dihydrogenphosphate and its addition salts formed with an organic or a mineral base.

9. The compounds of general formula I in accordance with claim 1, containing elements having an R or S configuration, or of racemic nature.

10. A method for obtaining dipeptide-like compounds of general formula I in accordance with claim 1:



(I)

wherein R_1 and R_2 each designate an acyl group derived from a saturated or unsaturated, straight or branched chain-carboxylic acid having from 2 to 24 carbon atoms, which is unsubstituted or bears one or more hydroxyl, alkyl, alkoxy, acyloxy, amino, acylamino, acylthio and ((C₁-24)alkyl)thio substituents,

wherein at least one of substituents R_1 or R_2 is an acyloxyacyl group,

subscripts m, p and q are integers ranging from 1 to 10, subscript n is an integer ranging from 0 to 10,


X and Y each designate a hydrogen or an acid group selected among the groups listed below

- carboxy [(C₁₋₅)alkyl]
- CH-[(CH₂)_mCOOH] [(CH₂)_nCOOH] with m = 0 to 5 and n = 0 to 5
- phosphono [(C₁₋₅)alkyl]
- dihydroxyphosphoryloxy[(C₁₋₅)alkyl]
- dimethoxyphosphoryl
- hydroxysulfonyl
- hydroxysulfonyl[(C₁₋₅)alkyl]
- hydroxysulfonyloxy [(C₁₋₅)alkyl]
- phosphono

either in neutral or charged form,

provided that at least one of substituents X and Y designates an acid group as specified above, either in neutral or charged form, A and B have the same meanings as specified above,

wherein amine functional groups in positions (q+1) and ω of a diamino acid of formula $H_2N(CH_2)_pCHNH_2(CH_2)_{q+1}COOH$ are blocked by a blocking reagent which readily undergoes acidolysis and hydrogenolysis, respectively, the carboxylic functional group still in free form is reacted with a reducing agent to yield a corresponding alcohol, the amine functional group in position (q+1) is freed and then acyl-substituted by means of a carboxylic acid functional derivative of formula R_2OH , wherein R_2 is as defined above, the terminal amine functional group is subsequently freed by hydrogenolysis to yield a diamino alcohol of general formula II




(II)

wherein R_2 designates an acyl group derived from a saturated or unsaturated, straight or branched chain-carboxylic acid having from 2 to 24 carbon atoms, which is unsubstituted or bears one or more substituents as defined above,

p and q designate an integer ranging from 1 to 10,

which diamino alcohol is condensed in presence of a peptide condensing agent in an inert solvent together with a ω -hydroxy, -amino or -thio amino acid compound of general formula III



(III)

wherein R_1 designates an acyl group derived from a saturated or unsaturated, straight or branched chain-carboxylic acid having from 2 to 24 carbon atoms, which is unsubstituted or bears one or more substituents as defined above


m is an integer ranging from 1 to 10,

n is an integer ranging from 0 to 10,

A is an oxygen, sulfur atom or an imino group NH

and X is an acid radical as specified previously which is optionally in an ester form


in order to yield a dipeptide-like compound of general formula IV



5

(IV)

wherein substituents and subscripts R_1 , R_2 , n , m , p and q have the same meanings as specified above, the alcohol functional group of which may be - if need be - alkyl or acyl or otherwise substituted by an alkyl or
10 acyl or an otherwise substitution reagent, in presence of a coupling agent, if needed, and subjected to a catalytic hydrogenation or some other deprotection method in order to obtain the derivative of general formula I




15

(I)

wherein substituents and subscripts A , B , X , Y , R_1 , R_2 , n , m , p and q have the same meanings as those given above.

11. A method for obtaining phosphodipeptide-like compounds of general formula I' in accordance with ~~anyone of claims 1 or 2~~ ^{claim 1}

20



(I')

wherein R_1 and R_2 each designate an acyl group derived from a saturated or unsaturated, straight or branched chain-carboxylic acid having
25 from 2 to 24 carbon atoms, which is unsubstituted or bears one or more


hydroxyl, alkyl, alkoxy, acyloxy, amino, acylamino, acylthio and ((C₁₋₂₄)alkyl)thio group substituents,

subscripts m, p and q are integers ranging from 1 to 10,

subscript n is an integer ranging from 0 to 10,

5 X and Y each designate a hydrogen atom or a phosphono group either in neutral or charged form,

wherein amine functional groups in positions (q+1) and ω of the diamino acid of formula H₂N(CH₂)_pCHNH₂(CH₂)_{q+1}COOH are blocked by blocking reagents which readily undergo acidolysis and hydrogenolysis, respectively, the carboxylic functional group still in free form is reacted with a reducing agent to yield a corresponding alcohol, the amine functional group in position (q+1) is freed and then acyl-substituted by means of a carboxylic acid functional derivative of formula R₂OH wherein R₂ is as defined above, the terminal amine functional group is subsequently freed by hydrogenolysis to yield an amino-alcohol of general formula II




(II)

20 wherein R₂ designates an acyl group derived from a saturated or unsaturated, straight or branched chain-carboxylic acid having from 2 to 24 carbon atoms, which is unsubstituted or bears one or more substituents as specified above,

p and q designate an integer ranging from 1 to 10


25 which amino-alcohol is condensed in presence of a peptide condensing agent in an inert solvent together with a ω-hydroxy amino acid derivative of general formula III' :




(III')

30

wherein R_1 is an acyl group derived from a saturated or unsaturated, straight or branched chain-carboxylic acid having from 2 to 24 carbon atoms, which is unsubstituted or bears one or more substituents,
 m is an integer ranging from 1 to 10,
 n is an integer ranging from 0 to 10,
 and X is dialkyloxy- or diaryloxy- phosphoryl radical of formula




to yield the peptide-like compound of general formula IV'



(IV')

wherein substituents R_1 , R_2 , m , n , p and q are as defined above,
 and R is radical which readily undergoes hydrogenolysis, the alcohol functional group of which can be - if need be - phosphorylated by a phosphorylating agent in presence of a coupling agent, if needed, and subjected to a two step catalytic hydrogenation in order to unblock the alcohol functional group optionally present on acyl groupe R_2 and the phosphate functional group and the second optionally present phosphate functional group of which can be subsequently unblocked by hydrogenolysis, in order to obtain the derivative of general formula V



(V)

wherein Y designates either a hydrogen atom or a phosphono group.


12. A method in accordance with ~~claims 10 or 11~~^{claim 10}, wherein the further step of salt formation is performed by means of a mineral or an organic base.

13. A method in accordance with ~~anyone of claims 10 to 12~~^{claim 10}, wherein the salt formation step is carried on by means of an organic or a mineral base intended for therapeutic use.

14. A method in accordance with ~~claims 10 or 11~~^{claim 10}, wherein the carboxylic acid R_1OH is 3-dodecanoyloxytetradecanoic acid.

15. A method in accordance with ~~claims 10 or 11~~^{claim 10}, wherein the carboxylic acid R_2OH is 3-hydroxytetradecanoic acid.

16. Pharmaceutical compositions containing as an active ingredient at least one compound of general formula I in accordance with claim 1 :



(I)

wherein R_1 and R_2 each designate an acyl group derived from a saturated or unsaturated, straight or branched chain-carboxylic acid having from 2 to 24 carbon atoms, which is unsubstituted or bears one or more hydroxyl, alkyl, alkoxy, acyloxy, amino, acylamino, acylthio and ((C₁₋₂₄)alkyl)thio group substituents,

subscripts m, p and q are integers ranging from 1 to 10,

subscript n is an integer ranging from 0 to 10,

X and Y each designate a hydrogen or an acid group either in neutral or charged form,

A and B, being identical or different from each other, are an oxygen, sulfur atom or an imino group,

together or in admixture with a non toxic, pharmaceutically acceptable, inert excipient or carrier

17. The pharmaceutical compositions in accordance with claim 16, wherein the compound of formula I is one of the type where X and/or Y designate a phosphono radical and further A and B designate an oxygen atom.

18. The pharmaceutical compositions in accordance with claim 17, wherein the active ingredient is in salt form with an organic or mineral base intended for therapeutic use.

19. The pharmaceutical compositions in accordance with ^{claim 16} ~~anyone of~~ ~~claims 16 to 18~~, wherein the active ingredient is in the form of a pure enantiomer or in the form of a mixture of stereoisomers.

add
Q2


add B1

add B4

ABSTRACT

The invention relates to the field of chemistry and more specifically to the field of medicinal chemistry.

5 The invention is directed to N-acyl-dipeptide-like compounds having the general formula I



(I)

10 wherein substituents A, B, X, Y, R₁, R₂, and subscripts n, m, p and q have the same meanings as those given in the claims.

The invention is equally directed to pharmaceutical compositions containing as an active ingredient at least one compound of general formula I either in acid or salt form with an organic or mineral base.

15 The compounds pursuant to the invention display interesting pharmacological properties which make them useful as drugs.

Please type a plus sign (+) inside this box → ☒

Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
 PTO/USPTO Form 100
 Instructions for use through 9/30/98. CMB 0651/0037

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it carries a valid OMB control number.

DECLARATION FOR UTILITY OR DESIGN PATENT APPLICATION

☒ Declaration OR
Submitted
with Initial Filing

☐ Declaration
Submitted after
Initial Filing

Attorney Docket Number

GET-084

First Named Inventor

BAUER et al

COMPLETE IF KNOWN

Application Number

PCT/IB99/01170

Filing Date

June 23, 1999

Group All Unit

Examiner Name

As a below named inventor, I hereby declare that:

My residence, post office address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought in this invention entitled:

NOVEL ACYL-DIPEPTIDE-LIKE COMPOUNDS, A METHOD FOR PREPARING
THE SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH
PRODUCTS

(Title of the Invention)

The specification of which

☐ is attached hereto
OR

☒ was filed on (MM/DD/YYYY)

06/23/99

as United States Application Number or PCT International

Application Number

PCT/IB99/01170

and was amended on (MM/DD/YYYY)

(if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37 Code of Federal Regulations, §1.56

I hereby claim foreign priority benefits under Title 35, United States Code §119 (a), (d) or §365 (a) of any foreign application(s) for patent or inventor's certificate, or §365 (a) of any PCT international application which designated or had its country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Not Claimed	Certified Copy Attached?	
				YES	NO
PCT/FR98/01396	France	06/30/98	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
PCT/IB99/01170	PCT	06/23/99	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

☐ Additional foreign application numbers are listed on a supplemental priority sheet attached hereto.

I hereby claim the benefit under Title 35, United States Code §119(e) of any United States provisional application(s) listed below.

Application Number(s)	Filing Date (MM/DD/YYYY)	<input type="checkbox"/> Additional provisional application numbers are listed on a supplemental priority sheet attached hereto.

(Page 1 of 5)

Burden Hour Statement: This form is estimated to take 0.5 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20503. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents and Trademarks, P.O. Box 1470, Alexandria, VA 22304-1470.

U.S.

Annex US, III, page 2

PCT Applicant's Guide - Volume II - National Chapter - US

Please type a plus sign (+) inside the box →



Under the Patent and Trademark Act of 1993, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

DECLARATION

I hereby claim the benefit under Title 35, United States Code §120 of any United States application(s), or §365(c) of any PCT international application designating the United States of America, filed before and, insofar as the subject matter of each of the claims of this application is not derived in one prior United States or PCT international application in the manner provided by the first paragraph of Title 35, United States Code §112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application Number

PCT Parent Number

Parent Filing Date (MM/DD/YYYY)

Parent Patent Number (if applicable)

☐ Additional U.S. or PCT international application numbers are listed on a supplemental priority sheet attached hereto.

As a named inventor, I hereby appoint the following registered practitioner(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

Name	Registration Number	Name	Registration Number
Bierman, Muserlian and Lucas	18,816		
Jordan B. Bierman	18,629		
Charles A. Muserlian	19,683		
Donald C. Lucas	31,275		

☐ Additional registered practitioner(s) named on a supplemental sheet attached hereto.

Direct all correspondence to:

Name	Charles A. Muserlian		
Address	Bierman, Muserlian and Lucas		
Address	600 Third Avenue		
City	New York	State	NY
Country	U.S.A.	Telephone	(212) 661-8000
		Fax	(212) 661-8002
		ZIP	10016

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application of any patent issued thereon.

Name of Sole or First Inventor:

☐ A petition has been filed for this unsigned inventor

Given Name

Jacques

Middle Initial

Family Name

BAUER

Suffix e.g. Jr.

Inventor's Signature

BAUER Jacques

Date

December 13, 2000

Residence: City

Saint-Prex CH

State

Country

Switzerland

Citizenship

Swiss & American

Post Office Address

Chemin de la Moraine 31, 1162 Saint-Prex, Switzerland

Post Office Address

City

Saint-Prex

State

Zip

1162

Country

Switzerland

☒ Additional inventors are being named on supplemental sheet(s) attached hereto

18/12 '00 11:14

0147590649

GEFIB

BIERMAN

0000

09721045 121800

US

PCT Applicant's Guide - Volume II - National Chapter - US

Annex US III, page 3

Print or type a plus sign (+) inside the box →



PROCESSED BY:
 Approved for use through 3/2000. US 0651 0037
 Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE
 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid PWB control number.

DECLARATION				ADDITIONAL INVENTOR(S) Supplemental Sheet			
Name of Additional Joint Inventor, if any:				<input type="checkbox"/> A petition has been filed for this unsigned inventor			
Given Name	Middle Initial	Family Name	Suffix				
Olivier, Richard		MARTIN					
Inventor's Signature			Date				
MARTIN, Olivier Richard			December 13, 2000				
Residence: City	State	Country	Citizenship				
Orleans	FR	France	Swiss				
Post Office Address				62 bis, avenue Dauphine, 45100 Orleans, France			
Post Office Address							
City	State	Zip	Country				
Orleans		45100	France				
Name of Additional Joint Inventor, if any:				<input type="checkbox"/> A petition has been filed for this unsigned inventor			
Given Name	Middle Initial	Family Name	Suffix				
Inventor's Signature			Date				
Residence: City	State	Country	Citizenship				
Post Office Address							
Post Office Address							
City	State	Zip	Country				
Name of Additional Joint Inventor, if any:				<input type="checkbox"/> A petition has been filed for this unsigned inventor			
Given Name	Middle Initial	Family Name	Suffix				
Inventor's Signature			Date				
Residence: City	State	Country	Citizenship				
Post Office Address							
Post Office Address							
City	State	Zip	Country				
Name of Additional Joint Inventor, if any:				<input type="checkbox"/> A petition has been filed for this unsigned inventor			
Given Name	Middle Initial	Family Name	Suffix				
Inventor's Signature			Date				
Residence: City	State	Country	Citizenship				
Post Office Address							
Post Office Address							
City	State	Zip	Country				
<input type="checkbox"/> Additional inventors are being named on supplemental sheet(s) attached hereto							